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Glycoproteins are a very large and biologically relevant class of proteins that 
comprise more than 50 % of proteins in the human body.  The glycosylation present on 
proteins, specifically N-linked glycosylation has been shown to be important for a variety 
of processes including protein folding, protein stability, and cell-cell interactions.  Many 
glycoproteins are currently being considered as therapeutic drug targets.  Glycosylation 
on proteins has also been shown to be altered with the onset of diseases, such as 
cancer, which has opened up the field of glycoproteomics, which aims to detect 
glycosylation changes for earlier detection of disease states.  Mass spectrometry is a 
versatile technique that is frequently utilized for the analysis of glycoproteins, and it is 
particularly useful in the detection of glycosylation present on proteins.  Most 
glycoproteins are prepared for mass spectrometric analysis by performing a protease 
digestion, followed by either a separation by HPLC or some other technique for 
enrichment of glycopeptides.  In this work, the protease digestion procedure was 
optimized for maximized protein sequence coverage and detection of N-linked 
glycopeptides and other post-translational modifications.  This method was applied to a 
recombinant glycoprotein that had never before been fully characterized by mass 
spectrometry and is a potential protein therapeutic as well as known to play a role in 
different types of cancer.  Furthermore, a mass spectrometric relative quantitation 
method was developed by creating glycosylation profiles from glycopeptides detected at 
individual glycosylation sites on different glycoproteins.  This method allowed for 
distinguishing between changes in protein concentration from changes in glycosylation.  
Lastly, glycoprotein structure and stability was probed by circular dichroism 
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spectroscopy before and after glycan removal on glycoproteins containing high 
mannose type glycans with the enzyme peptide-N-glycosidase F.  Protease digestion 
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CHAPTER 1  
INTRODUCTION 
1.1 Overview of glycoprotein analysis 
Glycoproteins are a large class of proteins involved in a wide variety of cellular 
processes and regulatory mechanisms. In fact, more than 50% of proteins found in 
serum are thought to be glycosylated.1-6  The oligosaccharides present on glycoproteins 
impart unique functionality onto a nascent protein chain, and this added functionality 
helps ensure that protein folding, transport, and signaling events are properly carried 
out.3, 5  Vital events such as protein degradation and modification of many cell to cell 
interactions are regulated by the glycan moieties comprising these glycoproteins.7-9 
Glycoproteins have been increasingly associated with biomarkers for many 
different types of cancer and other disease states. Specifically, these protein 
concentrations have been shown to be up or down regulated,10, 11 and changes in the 
typical glycosylation have been shown to occur with the onset of numerous 
pathologies.11, 12 Monitoring changes in glycosylation or glycoprotein concentration is a 
critical step in identifying new biomarkers to improve early detection of adverse 
pathological states.  
Glycoproteins are also an important class of pharmaceuticals.  The manipulation 
of glycosylation on proteins used in pharmaceutical development is becoming 
increasingly common, since the glycan moieties found on therapeutic glycoproteins 
have been shown to increase the protein’s efficacy and circulation half-life.13-15  Thus, 
additional care must be taken to ensure that the glycosylation engineered during drug 
design is metabolically compatible with the human body. Therefore, the ability to profile 
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glycosylation on proteins is important to a variety of fields, including biomarker 
discovery and glycoprotein drug development. 
Mass spectrometry has been shown to be an effective tool in glycoprotein 
analysis, as tandem mass spectrometry experiments, along with high resolution mass 
spectral data, work together to allow unambiguous identification and, at times, 
quantification of glycosylated proteins.2, 3, 5  Mass spectrometry is a technique that is 
capable of glycoprotein analysis in both large scale studies of multiple glycoproteins that 
have been extracted from tissues, serum, or other types of bodily fluids 
(glycoproteomics) and for analysis of a single glycoprotein, such as a purified 
recombinant glycoprotein with potential as a pharmaceutical candidate (therapeutics).  
The work described herein has applications that can be important for both 
glycoproteomics and therapeutic approaches. 
1.1.1 N-linked glycoproteomics 
Glycoproteomics is an analytical approach for studying glycoproteins; it relies 
heavily on the use of mass spectrometry.  This field is a subset of the larger field of 
proteomics, which focuses on the characterization, identification, and quantitation of 
proteins.3, 16  Glycoproteomic studies typically focus on the two most common types of 
glycosylation, O-linked and N-linked.  O-linked glycans are oligosaccharides that are 
covalently attached to a serine or threonine amino acid residue on some proteins.  This 
type of glycosylation has several core structures and no consensus amino acid 
sequence by which to determine where the glycan will be attached.17, 18  
Oligosaccharides undergoing N-linked glycosylation are attached through an 
asparagine residue containing the amino acid sequence Asn-Xxx-Ser/Thr and rarely 
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Asn-Xxx-Cys19, 20 where Xxx can be any amino acid except proline.  The core structure 
for N-linked glycosylation is a pentasaccharide consisting of two N-acetylglucosamine 
and three mannose residues.5, 17, 21  Figure 1 illustrates the different types of N-linked 
glycosylation. 
 
Figure 1. Representative types of N-linked glycosylation.  The conserved pentasaccharide core is boxed 
in red on the high mannose type glycan. 
 
One aspect of glycoproteomics is to measure relative changes in glycoproteins 
by either measuring changes in glycoprotein concentration or changes in the 
glycosylation present on the protein.  These studies are necessary for a variety of 
reasons, including monitoring alterations in the glycosylation and/or the protein 
abundance of glycoproteins during progression of certain diseases, such as cancer and 
congenital disorders of glycosylation (CDG),6, 18 where the overall goal is for early 
disease detection.  Thus, sensitive and quantitative analyses are extremely important 
for detection of disease states, as levels of glycoproteins in body fluids vary widely.22-24 
 The example above is a situation where it is generally necessary to retain the 
glycans on the protein for analysis; however, there are other applications for studying 
the glycoproteome that do not require retention of the glycans, once enrichment of the 
 4 
glycoproteome is completed.  For example, if the goal of the study is to determine 
protein expression level changes in glycosylated proteins,25-27 then retention of the 
glycans after glycoprotein enrichment may hinder the analysis. Additionally, studies 
aimed at determining glycosylation site occupancy, typically cleave off the glycans 
during the sample preparation steps.28, 29 
1.1.2 Glycoprotein therapeutics 
As the pharmaceutical industry continues to progress in the expansion of protein 
drugs, more and more glycosylated proteins are becoming targets for therapeutic 
development.  In fact, there are several glycoprotein drugs already on the market, such 
as erythropoietin,30 glycoprotein hormones (i.e. thyroid stimulating hormone, luteinizing 
hormone, etc.),31 and various human antibodies.32  Potential areas of growth include 
vaccine candidates like the envelope glycoprotein on the surface of the HIV virus, 
glycoproteins shown to be deficient in the body, and those glycoproteins that are found 
to be down regulated during disease progression, such as cancer.  Most protein drugs 
available today are expressed in a variety of cell lines including bacteria, fungi, insects, 
and mammalian cells.13, 14  Production of nonglycosylated proteins is achievable in a 
wider variety of expression systems compared to the cellular production of 
glycoproteins, because most nonglycosylated proteins are only dependent on 
transfecting the desired DNA into a particular cell line and stimulating the cell to produce 
the protein.  Thus, recombinant (nonglycosylated) proteins can be expressed in any of 
the cell lines mentioned above.  Glycoproteins, on the other hand depend heavily on the 
glycosylation machinery present in the Golgi apparatus of a cell.  Therefore, in addition 
to transfecting and producing glycoproteins in a cell, the cell line used is of utmost 
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importance because resulting glycosylation is cell dependent and not encoded into the 
DNA.13  Therefore, glycoproteins are commonly expressed in eukaryotic cell lines where 
glycosylation machinery is available as explained in more detail below. 
In many glycoproteins, one role of the glycans is to aid in protein folding; 
therefore, glycosylation is often necessary to produce properly folded and active 
glycoproteins.9, 33  Since bacteria cell lines, such as Escherichia coli, do not contain 
glycosylation machinery, proteins requiring glycosylation cannot be produced in these 
types of cell lines.13  Fungi and insect cell lines can produce glycosylation on proteins; 
however, the type of glycans formed from recombinant glycoproteins in these systems 
are very different from the glycans seen in human glycoproteins.13, 34  For example, 
humans produce N-linked glycoproteins with sialylated complex type glycans and 
fungi/insect cells produce N-linked glycans of the high mannose type (see Figure 1).9  
Therapeutic glycoproteins expressed in fungi and insect cell lines will inevitably have a 
much shorter circulation half-life in the body compared to the same glycoprotein with 
sialylated complex type N-linked glycans because mannose binding lectins recognize 
high mannose glycoproteins as non-self, and will remove these glycoproteins from the 
body.32, 35-37  Unfortunately, fungi and insect cell lines typically have much higher 
production yields compared to mammalian cell systems making these cell lines more 
amenable to the mass production required for recombinant therapeutic drugs.14, 37-39  
Mammalian cell systems produce glycoproteins with glycosylation most similar to 
human glycans.13, 14  One of the most commonly used mammalian cell expression 
systems for therapeutic glycoproteins is Chinese hamster ovary (CHO) cells.13, 14, 32  A 
problem with using CHO cells for producing recombinant glycoproteins, aside from the 
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lower production yields when compared to yeast or insect cells, is that the resultant N-
linked glycans contain two different types of sialic acids, N-acetylneuraminic acid and N-
glycolylneuraminic acid, but human N-linked glycans only comprise one type of sialic 
acid, N-acetylneuraminic acid.40, 41  There have been a few reports where glycoprotein 
drugs expressed in CHO cells have caused an immunogenic response.15, 31, 42  
Therefore, as interest in glycoprotein biopharmaceuticals increases, and a greater 
number of glycoproteins are designed for therapeutic use, new methods to evaluate the 
efficacy, metabolism, and in vivo circulation of these drugs will need to be developed, 
approved, and regulated by the Food and Drug Administration.   
1.2 Preparation for mass spectrometric analysis 
Many glycoproteins for mass spectrometric analysis come from very crude 
biological matrices.  For example, samples for glycoproteomics studies typically 
originate from different bodily fluids, such as serum.8  Recombinant glycoproteins, such 
as therapeutic drug candidates, are present either within the cells used for protein 
production or excreted into the cellular extract.43  In both of these situations, many 
purification steps are often required prior to mass spectrometry experiments.   
1.2.1 Enrichment of the glycoproteome   
 While approximately 50% of the proteins in the body are glycosylated, the 
remaining non-glycosylated proteins are also abundant, but not important for analysis of 
the glycoproteome.  To obtain optimal mass spectrometry (MS) data, efforts need to be 
made to remove as many of these interferents as possible.  Some research aimed at 
quantitative analysis of glycoproteins has a sample preparation component to separate 
out interfering proteins.  The two most common strategies for enriching glycoproteins 
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are lectin affinity chromatography and glycoprotein capture.  Other enrichment 
techniques can be found in the literature, as well.  Tables 1 describes the different types 
of glycoproteome enrichment strategies at the protein level, as well as a summary of 
advantages and concerns for each type. 
 
Table 1. Description of different types of enrichment for glycoproteins 
Type of Enrichment Ideal Application Key Considerations References 
Lecting Affinity 
Chromatography 
Analysis of a specific 
glycan type 
Lectins are somewhat promiscuous 
in their affinity for glycans.  Multiple 







Must remove glycans prior to MS, 





Analysis of 1 
glycoprotein 
An antibody is not always available 





1.2.1.1 Lectin affinity chromatography 
 Lectins are a class of mammalian and plant proteins that have highly specific 
binding sites for monosaccharide moieties or particular glycan chains containing certain 
branching patterns.56  Thus, lectins are often exploited for glycoprotein enrichment. Due 
to their high specificity, lectins are best utilized for glycoproteomics experiments when a 
specific type of glycosylated protein is to be purified from a complex mixture.57  For 
example, wheat germ agglutinin (WGA) has a specificity for sialic acid residues58 and N-
acetylglucosamine residues containing a β linkage, which is present on the 
pentasaccharide core of N-linked glycans.58, 59  Hill et. al. used WGA to enrich for 
glycoproteins in their glycoproteomic analysis.60  Many lectins, while very useful for 
enrichment of specific types of glycosylated proteins, are often too specific for 
glycoproteomics studies, when the goal is to profile all the glycosylation diversity 
present on the glycoprotein(s). As an alternative to using the WGA lectin, a series of 
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lectins can be employed to enrich a large variety of glycoproteins.61, 62  A variety of lectin 
combinations could be used.  The supplementary data from Tao et. al. lists many known 
lectins and their specificities,59 which could help researchers in choosing lectins for their 
experiments. Since the glycoforms are not cleaved during lectin affinity 
chromatography, this method is especially useful when the end-goal is to characterize 
the glycosylation on the proteins or peptides.   
1.2.1.2 Glycoprotein capture 
When the goal of the experiment is to quantify the glycoprotein, and not to 
characterize glycosylation, many researchers opt for glycoprotein capture systems to 
facilitate sample preparation.63-65  Glycoprotein capture strategies utilize hydrazide 
chemistry. A bead or resin containing a hydrazide functional group is covalently 
attached to a glycan through cis-diol groups present on some sugar moieties.34  The 
advantage to this strategy is that any accessible glycan on the glycoproteins that 
contains a cis-diol group will be attached to the bead, and all non-glycosylated 
proteins/peptides can then be removed.  Compared to lectin affinity chromatography, 
glycoprotein capture strategies are much less specific, allowing for a more general 
enrichment of the glycoproteome.25  Once the non-glycosylated proteins are 
successfully removed, an enzyme is added to remove the glycan from the protein.64  For 
glycoproteomics studies that seek to determine protein concentration changes, this 
method has proven to be excellent.  However, when information about the glycosylation 
is required, the capture method is not adequate.  Removal of 
glycoproteins/glycopeptides from the bead/resin necessitates loss of some or all of the 
glycan. 
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1.2.1.3 Isolating a single glycoprotein 
 When only one glycoprotein or one class of glycoproteins needs to be enriched, 
techniques that are specific to the glycoprotein of interest can be used.  For example, 
Wuhrer et. al. used Protein A immobilized onto Sepharose beads to enrich for 
Immunoglobulin G (IgG) proteins in human serum because of Protein A’s high affinity 
for IgGs.66, 67 
1.2.1 Protease digestion 
For analysis of proteins containing post-translational modifications (PTMs) by 
mass spectrometry, most proteins are cleaved by proteases to create several peptides, 
some of which contain PTMs.5, 44  MS analysis on intact proteins may prove difficult 
when trying to unambiguously identify the individual PTMs present, especially in cases 
where the specific site of attachment must be ascertained as well.45  This is especially 
true for glycosylated proteins, as glycoforms are typically heterogeneous for a given 
glycosylation site and often multiple glycosylation sites are present within the primary 
protein sequence as well.5, 45  Even when only one glycosylation site is present, 
individual glycoforms may not be resolved well enough within the MS data to allow for 
compositional assignment of the glycans.  This further necessitates the need for 
protease digestion in glycoproteins.   
There are many different options available for choosing proteases to cleave 
proteins.  Some proteases cleave before or after specific amino acid residues including 
trypsin,5, 46 endoproteinase GluC,46 and endoproteinase AspN,46 while other proteases 
cleave relatively non-specifically, such as proteinase K and pronase.5  Trypsin is one of 
the most commonly used proteases for mass spectrometric analysis of proteins.47  The 
 10 
specificity of trypsin allows for the  prediction of expected m/z values for resultant 
peptides, allowing for targeted MS data searches which help to speed up the data 
analysis process.5, 47  Under appropriate conditions, trypsin cleaves after Arg and Lys 
amino acid residues, which are fairly common in most proteins.48  A key advantage in 
the MS analysis of tryptic peptides is that an amine group is present due to the 
retainment of Arg and Lys residues at the C-terminal end of every peptide.48  The 
presence of these side chains help to ensure an addition of at least one proton to 
peptides during the ionization process, which helps to improve the ionization efficiency 
of tryptic peptides over peptides that do not contain amine groups at the C-terminal 
ends. 
Most proteolytic enzymes are not effective at cleaving proteins in their native 
conformations; therefore, proteins must be completely unfolded prior to the addition of 
the protease in order to achieve efficient digestion.49-51  Denaturants, such as 
chaotropes and detergents are among the most common reagents to unfold a protein.  
Chaotropes work by hydrogen bonding to a protein; competing with the intramolecular 
hydrogen bonding that keeps the protein structure intact.52, 53  Detergents allow the 
hydrophobic regions, which are typically buried in the center of the protein, to interact 
with the solvent, thereby unfolding the protein.52, 53  Detergents are excellent for 
unfolding proteins that are difficult to solubilize, e. g. membrane proteins, and new mass 
spectrometry friendly detergents, such as Waters corporation’s RapigestTM SF allow for 
the use of detergents in the denaturing step of the protease digestion process.54   
Many proteins contain disulfide bonds.  Although denaturing agents may 
effectively unfold a protein, which will allow for better access of the protein to the 
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protease’s cleavage site, the presence of disulfide bonds will impede protease 
efficiency.51  Therefore, most digestion procedures (except those where disulfide 
bonded peptides are sought) include a step to break (or reduce) the disulfide bonds.55  
After disulfide bonds are reduced, the free Cys residues that result are typically 
derivatized with an alkylating agent to ensure that reformation of disulfide bonds cannot 
occur.51  At this point, the protein should be completely unfolded, thereby maximizing 
the efficiency of the protease.  After protease digestion, the protein can either be directly 
injected onto a separation platform, such as reversed phase high performance liquid 
chromatography (HPLC) with data dependent mass spectrometry analysis or further 
enriched for PTM containing peptides, such as glycopeptides. 
1.2.2.1 Glycopeptide enrichment strategies 
 When the goal of the experiment is to quantify glycosylation on individual 
peptides, enrichment strategies are often needed at the peptide level as well.  To 
separate interferents at the peptide level (separating glycopeptides from their 
nonglycosylated counterparts) a sepharose-based enrichment, or chromatographic 
separation, is often implemented.68-70  Table 2 summarizes different glycopeptide 
enrichment strategies.  These enrichment methods exploit the chemical differences 
between glycan moieties and peptides, including differences in hydrophilicity, 
hydrophobicity, size, and net charge. Wada et. al., for example, developed an in-
solution extraction method using Sepharose CL-4B, a beaded hydrophilic 
polysaccharide polymer.  When a mixture of peptides and glycopeptides is added to the 
Sepharose CL-4B solution, the glycopeptides remain in the hydrophilic Sepharose CL-
4B fraction and the peptides are extracted out of solution with organic solvents before 
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elution of the glycopeptide fraction with aqueous solvents.68-70  Normal phase high 
performance liquid chromatography (HPLC) or hydrophilic interaction liquid 
chromatography (HILIC) can also be performed to separate glycopeptides from 
peptides.  Glycopeptides will be retained on a normal phase column longer than 
peptides, due to the hydrophilic glycan portion; thus, a separation of the two 
components will occur.71  An alternative to HILIC methods is to separate glycopeptides 
from peptides by hydrophobicity.  In these circumstances, reversed phase HPLC may 
be performed, and glycopeptides will tend to elute off the column before peptides.5, 70  
Alvarez-Manilla et. al.72 and Joenväärä et. al.73 used a glycopeptide enrichment method 
with size exclusion chromatography. Glycopeptides tend to be larger species compared 
to their peptide counterparts.  Thus, glycopeptides will elute earlier from a size exclusion 
column.72, 73  Strong cation exchange chromatography has also been shown to be 
useful for separating glycopeptides from peptides when there are sialic acids or other 
negatively charged species present on the glycopeptides.  The negative charge of the 




















Table 2. Description of different types of enrichment for glycopeptides 
Type of Enrichment Separation Mechanism Key Considerations References 
Sepharose 
Extraction 
Method has specific affinity for 
glycans 
Further separations may be 
necessary for analysis of 
complex mixtures 
[38-40] 
Normal Phase HPLC Glycopeptides tend to elute later 
than peptides 
Glycopeptides with high 
peptide contribution may 





Glycopeptides tend to elute 
earlier than peptides 
Glycopeptides with high 
peptide contribution may 





Glycopeptides are typically 
larger than peptides 
Not all glycopeptides are 





Many glycans on glycopeptides 
have negatively charged 
components, whereas peptides 
do not 
Not all glycopeptides 




1.3 Mass spectrometric analysis of glycoproteins 
Mass spectrometry (MS) is one of the most common techniques used for 
analysis of proteins, especially those containing post-translational modifications.  The 
high throughput, sensitivity, and selectivity keep mass spectrometry as the workhorse 
instrument for protein identification and quantitation.48  The instrumental design of a 
mass spectrometer consists of three main components:  An ionization source, a mass 
analyzer, and detector.  Most mass spectrometers used in protein analysis utilize either 
electrospray ionization (ESI) or matrix assisted laser desorption ionization (MALDI) for 
formation of gaseous ions.8  These techniques are considered “soft” ionization 
techniques, because analyte molecules are not broken apart during the ionization 
process.75  This ionization enables the MS detection of multiple analytes 
simultaneously.  Examples of mass analyzers include ion traps (3-D or 2-D), triple 
quadrupole, time of flight (TOF), Fourier transform – ion cyclotron resonance (FT-ICR), 
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and, most recently, the orbitrap.76, 77  Each of these analyzers has their own merits and 
limitations.77   
All mass analyzers are capable of producing MS1 data, which gives m/z values in 
a mass spectrum representative of all ions detected.  A mass spectrum helps to identify 
proteins and peptides by their m/z; however, proteins and peptides that have similar m/z 
values cannot be distinguished by their mass alone.  Tandem mass spectrometry (or 
MS/MS) experiments allow for isolation of a specific ion, which is then fragmented into 
pieces.78  The fragment ions detected help uniquely identify an ion present in a mass 
spectrum.  Collision induced dissociation (CID) is one type of tandem mass 
spectrometry experiment that involves the introduction of inert gas, such as helium, into 
the mass analyzer or collision cell.78  The inert gas collides with analyte ions that have 
been activated by an electric potential, where these collisions cause fragmentation of 
the analyte to occur.78 
Ion traps and triple quadrupoles are readily capable of performing tandem mass 
spectrometry experiments; however, the MS1 data is only available at unit resolution.77-
78  Although time of flight mass analyzers have the largest mass range, they are not 
amenable to tandem mass spectrometry experiments without the addition of some sort 
of collision cell (such as that found in the Qq-TOF).77  The resolution capable on a TOF 
instrument is greatly improved compared to the ion trap or triple quadrupole; yet, it is not 
as high as the FT-ICR or orbitrap mass analyzers.76, 77  The FT-ICR is capable of high 
resolution mass spectra, but it is costly to purchase, and the most difficult type of mass 
spectrometer to maintain, as it requires liquid helium and nitrogen for its super cooled 
magnet.79-81  The orbitrap is one of the most recent mass analyzers developed, and it is 
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capable of high resolution MS1 data similar to the FT-ICR, without the need for liquid 
nitrogen or helium.76  The work described in this dissertation focuses on utilizing 
electrospray as the ionization source, FT-ICR MS for high resolution mass spectra, and 
the linear ion trap for tandem mass spectrometry experiments as well as low resolution 
MS1 scans. 
1.3.1 Electrospray ionization 
Electrospray ionization (ESI) is one of the most common ionization methods used 
to analyze peptides and glycopeptides, since it can be readily coupled to a high 
performance liquid chromatrography (HPLC) system for online LC-MS and MS/MS 
analysis.82  Figure 2 is a schematic of the electrospray ionization process.83  A sample 
is introduced to the source through a capillary tube (ESI needle) with an applied 
potential between 2.5 to 5 kV, causing the analyte to become charged.82  When working 
in positive ion mode, negatively charged species are attracted to the inside of the 
capillary while positively charged species (containing the analyte) form a Taylor cone at 
the end of the needle, as shown in Figure 2.83, 84  Once the repulsive forces in the Taylor 
cone become greater than the surface tension, a spray of charged droplets will be 
released.  The electrospray source is heated to approximately 200 °C, causing the 
solvent in the charged droplets to evaporate.  A combination of solvent evaporation and 
Coulombic fission, due to increased space charge effects of the ions in the droplets as 
evaporation is occurring, allows for the formation of gaseous ions that enter the mass 
spectrometer.84, 85  The ions generated by ESI may be present in more than one charge 
state,84 and the presence of multiple charge states is often useful in the MS data, 
because it allows for the detection of proteins and peptides that would normally be well 
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beyond the mass range of most mass analyzers.82  At times, however, multiple charge 
states are problematic as their presence complicates MS data analysis, especially in 
cases where there are mixtures of proteins or peptides present.82 
   
 




Lastly, some considerations are necessary for obtaining sufficient ionization 
efficiencies with ESI.  Positive ion mode is typically utilized for ESI on many peptides 
and glycopeptides because of amine groups present on peptides that are favorable for 
protonation.  To enhance the ionization of peptides, small amounts of acid (typically 0.1 
to 0.5 % formic or acetic acid, respectively) are added to the solvent to provide excess 
protons for protonation of peptides and glycopeptides.82  Solvent conditions need to be 
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fairly volatile to aid in the de-solvation process.  Typical solvents include mixtures of 
water and organic solvents, such as acetonitrile and methanol.82  The presence of salts 
inevitably decreases ionization efficiency as salts are nonvolatile and alter droplet 
formation from the taylor cone.86   Consequently, salts need to be minimized whenever 
possible.  This is accomplished by using buffers that are ESI-friendly, such as Tris or 
ammonium bicarbonate for protein preparation.  
1.3.2 FT-ICR mass spectrometry 
Fourier transform – ion cyclotron resonance mass spectrometry (FT-ICR MS) is 
based on the principle that ions in a magnetic field will move in a direction perpendicular 
to that field, thereby forcing ions to move in a circular motion.79-81  Equations 1.1 and 1.2 
describe the different forces in play when ions are in the presence of a magnetic field; 
where F is force, e is the charge of an electron, v is velocity, B is magnetic field 
strength, m is mass and r is the radius of ion motion.81  For stable movement of ions 
within the magnetic fields, a balance between Equations 1.1 and 1.2 needs to be met as 
is shown in Equation 1.3.81   
 
















Because ions move in a circular path an angular frequency (ω) is considered and its 
relationship to velocity is shown in Equation 1.4.81  Rearranging Equation 1.3 in terms of 
magnetic field strength (B) and incorporating in the angular frequency term, Equation 
1.5 clearly shows that under the same magnetic field strength, ions of different m/z will 







One arrangement for an FT-ICR mass analyzer is composed of 6 plates placed 
together as a 6-sided cubic box that is located in the presence of an external magnetic 
field.79-81  Figure 3 illustrates the FT-ICR cell and an ion traveling within the cell.  Plates 
facing opposite one another have similar roles, where two plates keep ions trapped in 
the mass analyzer (trapping plates), two plates are for ion excitation (excitation plates), 




Figure 3. Illustration of an FT-ICR cell showing the different plates where there is a second plate of the 
same type opposite to the one labeled.  The circular arrow describes an ion in motion in the FT-ICR cell. 
 
The trapping plates (one of which is the entrance to the FT-ICR cell) are set 
perpendicular to the magnetic field direction so that after ions enter the cell, a small 
positive potential can be applied (if detecting positive ions) to the trapping plates to keep 
ions trapped within that cell.79, 81  Once ions are trapped, they will begin to move in a 
circular path, as shown in Figure 3, due to the external magnetic field.  For detection of 
ions, a sinusoidal potential is scanned and applied to the excitation plates over a 
frequency range large enough to excite all the ions present in the cell.79, 81  This results 
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in an increase in kinetic energy of the ions causing the orbit of ions to increase and 
packets of ions to form by m/z.80, 81  As the ions pass by one detector plate, a small 
image current is induced and measured.79-81 Since there are two detector plates 
opposite one another, an alternating current is induced as the ions pass by each plate.79  
The sinusoidal wave that results from the alternating current of ions passing the 
detector plates can be transformed into a frequency through the use of Fourier 
transform equations.79  Using equation 1.5, the frequency of ion motion in the FT-ICR 
cell is converted to m/z to construct a mass spectrum.  This method for the detecting 
ions allows for very accurate frequencies to be obtained for the ion packets, resulting in 
high resolution mass spectra.79-81 
1.3.3 Ion trap mass spectrometry 
There are two different types of ion trap mass spectrometers commercially 
available; 3-D and 2-D (or linear) ion traps.87  Both instruments work in the same 
manner to separate ions by m/z where ions are first stored, or trapped, within the 
instrument and then ejected sequentially by m/z to construct a mass spectrum.87, 88  The 
3-D ion trap uses only RF frequencies to store ions within the trap, whereas the linear 
ion trap utilizes a DC potential to trap ions in the axial direction and RF potentials for 
trapping ions in the radial direction.87   
There are several advantages in using linear ion traps over 3-D ion traps, 
including the ability to trap more ions due to an increased analyzer volume, lower space 
charge effects, (as ions are focused onto a line across the center of the linear ion trap 
rather than a point in the center of the 3-D ion trap), and the ability to eject ions in a 
perpendicular direction to entrance of the trap, enabling the use of two detectors as 
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opposed to only one for ion detection.87-89  The design changes employed in the 
development of linear ion traps allow for greater sensitivity and dynamic range in the 
mass spectral data.87-89 
 Linear ion traps look most similar to a quadrupole where either 4 circular or 4 
hyperbolic rods are positioned in a circular fashion, where opposite rods are parallel to 
one another, as shown in Figure 4, which represents a schematic of the linear ion trap.  
In contrast to the quadrupole, rods in linear ion traps are separated into 3 sections; the 
front, center, and back, where the front and back sections are typically 12 mm in length 
and the center section is 37 mm in length.88-89  The separation between sections allows 
for different DC potentials to be applied in each individual section when needed.88  For 
example, to keep ions trapped in the mass analyzer, a higher DC potential will be 
applied to the front and back sections compared to the center section to repel ions away 
from the edges of the trap in the z direction (see Figure 4).88  To contain ions in the x 
and y directions (see Figure 4) an RF potential is applied to all the rods where rods 
opposite one another are in phase, which creates a restoring force that keeps the ions 




Figure 4. Schematic of a linear ion trap mass analyzer showing the quadrupole hyperbolic rods in three 
sections and the exit slit where ions are ejected from the trap in the x direction.  This figure was adapted 
from Schwartz et. al.88 
 
 
For ion isolation, activation, and detection, resonance excitation is used. Each 
ion present in a quadrupolar field moves at a specific frequency within the field, where 
ions of different m/z move at different frequencies.89  To keep ions in the trap, the 
movement of the ions must be less than the dimensions of the trap, otherwise ions will 
hit the rods and not be detected or will leave the trap through the exit slits.89  Ion stability 
within the linear ion trap at different RF potentials can be predicted through the use of 






where U is the direct potential, VRF is the RF potential, Ω is the angular frequency, r0 is 
the distance from the center of the trap to one of the rods, and m/z is the mass to 
charge ratio.89  When these two parameters are plotted against one another the regions 
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of overlap in the plot are representative of regions where ions are stabile (i. e. ions will 
not hit the rods, but move within the confines of the trap).87-89  Douglas et. al. show a 
representative Mathieu stability plot illustrating the areas where an ion will be stable in a 
linear ion trap.89  Once an ion in a quadrupole ion trap system reaches a q value of 
0.908, it will become unstable and leave the trap.89  For ion ejection and detection, in 
the radial direction, the RF potential is scanned such that all the ions in the trap become 
unstable (or reach a q value of 0.908) and are removed from the trap and detected by 
their m/z values.89   
Ion traps are particularly well suited for tandem mass spectrometry experiments 
because of the ability to isolate ions of one m/z in the trap.  Ion isolation is achieved by 
removing all ions except the m/z of interest (or precursor ion).  Two different 
mechanisms are used to remove unwanted ions.  The first method is to scan the RF 
potentials to cause the ions below the precursor m/z to reach a q of 0.908 and become 
unstable.89  In order to eject ions above the precursor m/z a method called resonance 
ejection is used.88, 89  This method takes advantage of the fact that each ion has a 
different frequency of motion.89  When the RF frequency matches an ion’s frequency of 
motion it causes the amplitude of the ion trajectory to increase and eventually the ion 
will either hit a rod or leave the trap.78, 89  A shorter RF frequency pulse is used to 
activate ions away from the center of the trap, but not far enough away from the center 
to remove the ions from the trap.  This ion activation in combination with the addition of 
inert gas causes fragmentation of the precursor ion for CID MS/MS experiments.78, 89  
The RF potential is scanned after fragmentation to detect the fragment ions.89 
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The experiments herein utilize two linear ion trap (LTQ and LTQ Velos) mass 
analyzers, both manufactured by ThermoScientific, to achieve MS analysis of peptides 
and glycopeptides.  The LTQ used is part of a hybrid mass spectrometer where it is 
coupled to an FT-ICR MS.  This instrumental set-up was used to obtain high resolution 
mass spectra with the FT-ICR MS, while MS/MS experiments were performed within the 
LTQ component.  The LTQ Velos mass analyzer was used as a stand-alone mass 
spectrometer, and though the MS1 data from the LTQ Velos cannot match the resolution 
possible on the FT-ICR MS, the MS/MS data acquired on the LTQ Velos are improved 
compared to the LTQ by higher sensitivity and faster scan rates.90, 91  Figure 5 illustrates 
schematic of the LTQ (Figure 5A) and the LTQ Velos (Figure 5B) where key differences 
can be elucidated.   
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Figure 5. (A) Schematic of a ThermoScientific LTQ mass spectrometer and (B) schematic of a 
ThermoScientific LTQ Velos mass spectrometer. Note that the ion transfer tube is about half the length in 
the LTQ Velos (B) compared to the LTQ (A), the skimmer and tube lens from the LTQ (A) were replaced 
with an S-lens (B), and there are 2 linear ion traps in tandem in the LTQ Velos (B) with differential 
pressures and only 1 linear ion trap in the LTQ (A).  The schematics are adapted from Second et. al.90 
and Olsen et. al.91 
 
One change that was implemented into the LTQ Velos design includes a different 
mechanism for focusing ions into the mass analyzer.  The LTQ uses a tube lens and 
skimmer system for ion focusing whereas the LTQ Velos uses an S-lens (or an Stacked 
Ring Ion Guide),91 which consists of a set of flat ring electrodes that are spaced further 
and further apart from one another, as shown in Figure 5B.  Instead of a DC potential 
gradient being applied to focus ions toward the mass analyzer, the S-lens uses RF 
potentials where the odd and even ring electrodes are of opposite phases, which keeps 
ions focused towards the center of the S-lens lens as ions are guided into the linear ion 
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trap.90, 91  The use of RF potentials for ion focusing in the S-lens system has been 
shown to increase the efficiency of ions that make it to the trap.92   
The second innovation incorporated into the LTQ Velos is the use of two linear 
ion traps, rather than just one (see Figure 5).  The first trap is maintained at a higher 
pressure, thereby allowing better collisional cooling and faster ion activation in collision 
induced dissociation (CID) MS/MS experiments, while the second trap is maintained at 
at a lower pressure to be utilized solely for ion ejection toward the detectors.  This dual 
pressure system has been shown to increase sensitivity and lower scan rates compared 
to the LTQ.90, 91   
The last major innovation in the LTQ Velos is the use of predictive automatic gain 
control (AGC).  Some ion trap mass spectrometers (including the LTQ) take a pre-scan 
of mass spectrum prior to the analytical scan that the user sees in the MS software.  
This pre-scan allows the instrument to assess the ion intensities and dynamically adjust 
injection time.  A pre-scan takes ~ 30 ms to perform and is repeated for every spectrum 
taken.  The predictive AGC that is utilized in the LTQ Velos removes the pre-scan, and 
uses prior MS1 data that has already been collected to assess ion intensities and adjust 
injection times.  This combination of improvements made in the LTQ Velos mass 
analyzer contribute to the increased sensitivity, high dynamic range, higher resolution, 
and dramatically shorter scan rates for MS/MS data compared to the LTQ.90, 91 
1.3.4 Identification of peptides and glycopeptides 
For identification proteins and their post-translation modifications, MS analysis is 
performed after proteolytic digestion of a protein(s) into peptides.  When possible, mass 
spectra are obtained on a high resolution instrument, and tandem mass spectra are 
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utilized to aid in compositional elucidation of peptides.93  Because protease digestions 
typically yield several peptides, data analysis of peptides and PTM-containing peptides 
have complicated MS data where large proteins or mixture of proteins can take weeks 
or even months for complete manual data analysis.   
To ease the data analysis bottleneck, computer programs are available that can 
help analyze tandem mass spectra.  Databases such as Mascot,94 SEQUEST,95 and 
X!Tandem96 can be used to help identify peptides in the MS/MS data.  Parameters can 
be set to search for some PTMs, such as phosphorylation and methionine oxidation.94  
Additionally, artifacts of the protease digestion can be take into account, such as 
alkylation of Cys residues, alkylation of the N-terminus, and carbamylation of the N-
terminus when urea is used for denaturation.94  After a program examines the MS/MS 
spectra, a list of “hits” or peptide matches is obtained.  The matches identified in the 
database programs can be compared to the MS/MS data for confirmation of identified 
peptides.  The use of database programs does indeed speed up MS analysis time, 
however, manual data analysis is still important.97  For manual analysis of peptides, 
characteristic ions (b and y ions in CID MS/MS data) are searched for in the MS/MS 
data.  When the monoisotopic mass is near the calculated monoisotopic mass (mass 
accuracy depends on the mass analyzer used for MS analysis) for MS1 data and 
MS/MS data contains appropriate fragment ions, a peptide can be considered 
identified.46   
There are certain modifications that database programs do not take into account. 
Two examples include partial alkylation of Cys residues on peptides containing more 
than one cysteine and glycosylation of peptides.  Glycopeptides are not searchable in 
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peptide database due to the high heterogeneity of glycans present on proteins, making 
the prediction of m/z values for potential glycopeptides quite complex.  Thus, 
glycopeptide MS data is typically still analyzed manually.  MS/MS spectra that are 
indicative of glycopeptides contain certain marker ions such as m/z 366, 528, and 657 
when CID is used for MS/MS data collection.5  The presence of marker ions and losses 
of sugar residues (observed by subtracting the mass of different monosacchrides from 
the precursor ion mass) help to identify the glycan composition of glycopeptides.  The 
peptide portion is identified from the difference in the mass of the precursor ion and the 
mass of the glycan portion.5  There are a few software programs and databases 
available for aiding in MS analysis of glycopeptides, such as GlycoPep DB,98 GlycoPep 
ID,99 and GlycoMiner,100 however, none of the available programs can analyze data as 
completely as the peptide database programs like Mascot.  Until that time, interpretation 
of glycopeptides will be primarily completed manually. 
1.3.5 Quantitation Strategies 
 There are two basic strategies applied for relative quantitation of the 
glycoproteome; differential labeling and label-free analysis.  Both strategies have their 
associated advantages and disadvantages.  Many biomarker discovery experiments 
seeking to determine protein expression level changes employ labeling techniques to 
achieve relative quantitation between healthy and diseased samples.26, 101  On the other 
hand, glycopeptide-based strategies typically encompass label-free approaches for 
construction of a glycosylation profile showing the distribution of glycoproteins present 
within a biological sample.67, 68  These and other applications of quantitative 
glycoproteomics studies are described in more detail below. 
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1.3.5.1 Quantitation of glycoproteins after glycan release 
Many quantitative glycoproteomics studies can be conducted by quantifying 
peptides after glycan removal.  These studies could be done, for example, to calculate 
protein expression levels relevant to glycoprotein produced, to evaluate the amount of 
glycoprotein bound to a lectin column that has defined glycan specificity, or to measure 
and define glycosylation site occupancy, as cleaving the glycans introduces a 1 Da 
mass shift in the peptide mass.  [It should be appreciated, however, that direct 
quantification of co-eluting peptides with a 1 Da mass difference can be problematic.  
Therefore, when the goal is to measure glycosylation site occupancy, labeling strategies 
are generally incorporated to increase the mass difference between the glycosylated 
and nonglycosylated compounds.]  Regardless of whether the goal is to monitor site 
occupancy, glycosylation expression level, or quantify glycoprotein binding to lectins, all 
three types of experiments generally involve cleaving the glycans after the initial 
glycoprotein selection steps and quantifying the bare peptides.   
Removal of glycans is often advantageous for many reasons.  1) Glycosylated 
peptides have a high degree of heterogeneity, due to the multiple glycoforms that can 
be attached to the peptide portion.  Thus, when glycopeptides are identified in mass 
spectra, a peptide containing just one glycosylation site produces many spectral peaks, 
which correspond to those different glycoforms present along the peptide backbone.  
This heterogeneity contributes to difficulty in obtaining quantitative data with respect to 
the peptide sequence.102  2) The glycopeptide ion signal is spread among all the 
different glycoforms, lowering the abundance of the MS signal of each peak.  3) 
Glycopeptides are more difficult to analyze, due to the need to deduce both the peptide 
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composition and the glycan composition.5  4) Additionally, negatively charged glycans 
commonly present in most mammalian glycoproteins, such as or sialic acid residues, 
also negatively impact the MS signal of glycopeptides detected in positive ion mode.103  
The following sections describe differential labeling and label-free quantitation 
techniques that achieve quantitative glycoproteomics by analyzing (de-glycosylated) 
peptides from the glycoproteome.  Typical work flows of glycoproteomics studies where 
the glycans are cleaved prior to mass spectral analysis are described in Figure 6.  
Biological samples are first enriched for glycoproteins primarily by lectin affinity 
chromatography or glycoprotein capture, followed by protein digestion with a protease 
such as trypsin.  After protease digestion, the glycans are cleaved from the protein for 
mass spectrometry analysis, where finally the peptide data is evaluated for quantitative 
changes using either isotopic labeling or a label-free approach. 
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Figure 6.  Flow chart summarizing experimental/data analysis protocols of the quantitative analyses from 
glycoprotein samples that are eventually de-glycosylated and analyzed as peptides by mass 
spectrometry. 
 
1.3.5.1.1 Quantitation methods for de-glycosylated peptides using isotopic 
labeling 
 These methods are best used when only two types of samples are being 
compared, such as in biomarker studies in which healthy (control) samples are profiled 
and evaluated against diseased-state samples.26, 62, 101 There are a variety of options 
available for differential labeling of peptides, including those that utilize the incorporation 
 31 
of stable isotopes into the amino acid sequence, as well as methods that instead require 
the derivatization of the peptides with isotope-enriched tags.  The greatest advantage of 
these strategies, with respect to label-free methods, is that samples being compared 
are mixed and analyzed simultaneously.  Simultaneous analysis of the two samples is 
not only more efficient; it removes much of the signal variability associated with run-to-
run inconsistencies.  Mixing the samples together also eliminates slight differences in 
retention times for peptide peaks, which is a common problem for samples not run 
simultaneously.  Moreover, labeling can be very useful in detecting subtle changes 
within samples.104  
Stable isotope labeling is a powerful tool for comparing glycosylation changes 
across a variety of biological samples.  Quantitation using this strategy is accomplished 
by calculating the ratio of intensities between the “light” and “heavy” sample 
populations.  This ratio is then used to determine if protein concentration is up- or down-
regulated.  Stable isotope labeling is particularly helpful when identifying cell-surface 
glycosylation changes between complex biological sample types, as demonstrated by 
Wollscheid et. al. in the comparison of cell surface glycosylation of T and B cells during 
neuronal activation.25  In this work, the glycoproteins were “pre-labeled”, using the 
SILAC (Stable Isotope Labeling of Amino acids in Cell culture) method.  The cell-
surface glycoproteins were captured using a bi-functional linker (one side with a 
hydrazide functional group to affix covalently to the glycans of cell surface 
glycoproteins, the other, a biotin tag that attaches to streptavidin beads for glycoprotein 
purification).  After tryptic digestion, the glycopeptides were released with Peptide N-
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Glycosidase F (PNGase F).  Protein concentration was inferred based on the 
differences in abundance of the various isotopically labeled peptides.   
Stable isotopic labels were also used to quantify protein expression of the serum 
glycoproteome in lung cancer patients by Ueda et. al.26  In this analysis, glycoproteins 
were enriched using serial lectin affinity fractionation, and the isotopic label was 
incorporated by 13C6-2-Nitrobenzenesulfenyl labeling of tryptophan residues.  This 
method has been reported to be highly sensitive, as the screening was focused toward 
low-abundance proteins.   
Numerous other research groups have focused on novel quantification strategies 
making use of H218O as the isotopic label.28, 29, 74, 101  For example, Hülsmeier et. al. 
introduced a mass difference of 2 Da between the control and experimental samples by 
diluting PNGase F, the deglycosylation enzyme, in heavy water (H218O) or non-labeled 
water (H216O).  In these experiments, the isotopic label is introduced at the Asn that was 
formerly glycosylated.  As the N converts to D, one 18O is incorporated.  This strategy is 
particularly useful when the research goal is to probe site occupancy of proteins.  
Hülsmeier’s work is also notable in that the glycoproteins were initially captured using a 
sepharose affinity resin.28 
A manuscript published by Liu et. al. reported the monitoring of changes in 
glycosylation from a patient with ovarian stage II b cancer vs. a healthy control, where 
three heavy 18O atoms were incorporated into one of the samples by labeling the 2 O 
atoms at the C-terminus (during tryptic digest) and the site of deglycosylation, after 
PNGase F treatment.  This gave a 6 Da mass shift between the two samples, allowing 
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for complete resolution of healthy and diseased peptide peaks in the mass spectral 
data.29  
Additionally, other glycoproteomics studies have used labeling approaches 
where the stable isotope is incorporated at the N terminus. For example, Qiu et. al. used 
acetic anhydride to differentially label glycoproteins from serum that were retained on 
lectin columns.  The lectin encoded for the glycoform type (bi-, tri-, or tetra-antennary) 
and the resulting glycans were cleaved prior to MS analysis.61  These studies 
demonstrate that, through the use of serial lectin affinity chromatography, tri- and tetra-
antennary N-linked glycopeptides were separated from biantennary glycopeptides.  
After the separation, the isotopically labeled samples allowed for a quantitative 
comparison of branching patterns in serum glycoproteins.61  
 Finally, quantitative glycoproteomics can be completed using iTRAQ (isobaric 
Tag for Relative and Absolute Quantitation) reagents.57, 62, 65  Deglycosylated peptides 
or glycoproteome enriched samples are tagged with iTRAQ reagents and mixed prior to 
mass spectrometric analysis.  One advantage of this technique over other labeling 
strategies is that up to four105 or, more recently, eight106 samples can be analyzed at a 
time.  Additionally, as a result of the isobaric tag, MS1 data is not diluted over multiple 
peaks, which is the case for traditional isotopically labeled samples.  To quantify using 
iTRAQ, tandem mass spectrometry (MS/MS) data is analyzed for reporter ions (ions of 
the naked iTRAQ reagents) and the ratio in the MS signal among reporter ions is used 
to determine up- or down-regulation of glycoproteins.65, 105, 106  
Furthermore, the use of iTRAQ has become a very useful quantitative tool in 
biomarker studies.62, 65  For example, Zhou, et. al. captured glycoproteins from tear fluid 
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using hydrazide chemistry and used iTRAQ to compare glycoprotein concentrations 
between control and climatic droplet keratopathy patients.65  Lee, et. al. used multiple 
lectins to enrich glycoproteins from plasma and made use of iTRAQ for biomarker 
analyses on a comparative study between healthy and hepatocellular carcinoma 
specimens.62   
1.3.5.1.2 Label-free quantitation methods for deglycosylated peptides  
These methods described herein are another attractive option for 
glycoproteomics studies.  One advantage to label-free studies is that there is no 
limitation to the number of samples for comparison, as is the case with labeling 
strategies.  Additional reagents and extra sample preparation steps are also 
unnecessary, yielding a simpler work-flow.63  The key disadvantage of label-free 
methods, however, is that the data analysis can be more challenging.  This is due to a 
variety of reasons.  1) Since all the samples in a label-free analysis are not analyzed 
simultaneously on a mass spectrometer, run-to-run variability in signal intensity must be 
taken into account. Thus, label-free approaches can use normalization techniques to 
overcome the instrumental variability.107, 108  2) Label-free studies are often repeated 
multiple times to ensure reproducibility among samples.27, 107  3) LC-MS experiments 
require alignment, as the peptide peaks of interest have slight shifts in retention time 
among sample runs.27, 60  Quantification applied to label-free approaches is done by 
comparing either the relative intensity of peptide peaks in mass spectra or the peak 
area under the curve of the extracted ion chromatograms for a given peptide.  Often, 
software programs such as SuperHirn27 and ProteinQuant107, 108 are utilized to 
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accomplish the complex spectral alignment and data processing required for label-free 
studies.   
 Zhang et. al. demonstrated that it is possible to do a very simple quantitative 
analysis on serum glycoproteins by using glycoprotein capture for enrichment and label 
free quantitation (without normalization).109  The capture strategy greatly reduced 
sample complexity and allowed for direct comparison of relative abundances from 
relevant peptide peaks between healthy and cancerous mouse serum.  To validate this 
non-normalized label-free analysis strategy, N-termini of captured peptides were labeled 
with heavy and light succinic anhydride.  Results from the labeled component were 
similar to the label-free analysis.  It was indicated in this work, however, that variability 
was detected among relative abundances of replicate samples (i.e. the 3 healthy serum 
samples that were analyzed); however, differences were evident between healthy and 
cancerous peptides.109 
 Another method commonly used to quantify changes among samples is to 
calculate the area under the curve of a particular peptide peak from extracted ion 
chromatograms.27, 60, 63, 107, 108  Schiess et. al. analyzed drisophila melanogaster cells to 
quantify changes in the cell-surface glycoproteome before and after perturbation of the 
cell with chemical reagents that are known to affect intracellular signaling events.27  As 
described above, a bi-functional linker was used to capture cell-surface glycoproteins 
for analysis of the deglycosylated N-linked peptides.  To quantify changes in the cell-
surface glycoproteome, a ratio between perturbed peptide peak areas and control 
peptide peak areas was calculated.  In order to maximize reproducibility, 3 cells were 
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analyzed in triplicate, yielding 9 replicate sample sets that were averaged together for 
comparison between the perturbed and non-perturbed cells.27  
The practice of calculating a ratio of peak areas to describe changes between 
two different sample sets has also be done by Hill et. al. in two separate cancer-related 
studies.60, 63  Glioblastoma (cancerous) cells were exposed to a drug believed to 
decrease the proliferation of tumors.  Glycoprotein capture was utilized to enrich for 
glycoproteins on cells before and after drug treatment.63  A second study by Hill et. al. 
was done on model tumor cells to compare changes in glycoprotein expression levels 
before and after the addition of protein transforming growth factor beta, which is known 
to affect tumor cells.  For this particular study, lectin affinity chromatography was used 
to enrich for glycoproteins.60  In both sets of experiments, each sample was run in 
triplicate to improve reproducibility,60, 63 and a ratio between treated and untreated 
peptides peak areas was calculated to determine relative changes in glycoprotein 
abundance.  
 Other researchers have sought to remove the run-to-run variability that is 
common for label-free quantitative analysis by applying a normalization strategy during 
data analysis.  Mann et. al. developed software tools, entitled ProteinQuant Suite, for 
automated proteomic quantitative analysis.108  This program aids in removing run-to-run 
variability by either dividing the peak area (in SIM chromatogram) of a peptide peak by 
the sum of the peak areas of all peptide peaks in a given sample, or by dividing the 
peak area of a peptide peak by the peak area of an internal standard.108  Madera et. al. 
used ProteinQuant to compare changes in glycoproteins due to differences in lectin 
matrix preparations.107  Normalization was completed by summing the peak areas of all 
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peptide peaks present in a sample.  It should be noted that the glycans were not 
removed in this study; however, the quantitative work-up was for the non-glycosylated 
peptides only.107 
1.3.5.2 Quantitation of glycopeptides 
At times, it is necessary to retain the glycans on glycoproteins during analysis of 
glycopeptides.  Changes in glycosylation may occur without protein expression level 
changes as the glycosylation pattern is very much dependent on changes in the 
localized cellular environment.5, 17, 18, 110  It is also known that different glycosylation 
patterns may occur on different glycosylation sites of glycoproteins.111  Thus, it is 
sometimes necessary to profile glycosylation changes in a site-specific manner by 
analyzing glycopeptides directly.68, 111  In addition to naturally occurring changes in 
glycosylation at specific glycosylation sites, disease progression of certain cancers and 
CDG are well known to change glycosylation.102, 112  Tajiri et. al., for example, 
developed a method to site-specifically monitor changes in fucose levels in known 
fucosylated proteins, as fucose is a biomarker for certain cancers.112  In glycopeptide-
based strategies, quantitation is carried out in a label-free fashion, by using either the 
relative intensity (peak height) or peak areas from extracted ion chromatograms. The 
intensities can be used directly to compare samples67 or glycopeptide peaks can be 
normalized by dividing the intensity of a given glycopeptide peak by the sum of all 
intensities from all glycopeptide peaks present in either a mass spectrum,68 window of 
retention time,113 or the sum of peaks for a specific glycosylation site.114  Biomarker 
analyses and other experiments aimed at comparing two samples to one another 
typically calculate a ratio for comparison between samples, as Uematsu et. al. did to 
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compare murine dermal and epidermal glycopeptides.115  Glycopeptide-based 
methodologies are illustrated in Figure 7.  When working with complex biological 
mixtures, such as serum or cell culture, an affinity purification step may be employed for 
initial enrichment for glycoproteins.  Glycoproteins are proteolytically digested, followed 
by glycopeptide enrichment.  Exploitation of the differences between peptides and 
glycopeptides are utilized to enrich for glycopeptides.  Potential differences include 
changes in hydrophilicity, hydrophobicity, and charge (in the case of sialylated, sulfated, 
and phosphorylated N-linked glycans).  Mass spectrometry is often used for 
glycopeptide detection, and identification of the glycopeptides is typically completed with 
the aid of web-based software such as  such as GlycoMod,116 GlycoPep DB,98 
GlycoPep ID,99 and GlycoMiner.100   
 
Figure 7.  Illustration of the most common protocols for quantitative analyses of glycopeptides by mass 
spectrometry. 
 
1.3.5.2.1 Label-free quantitation methods for glycopeptides 
The label-free approach is the only currently adopted approach for glycopeptide-
based glycoproteomics strategies.  In these types of studies, researchers may be 
keenly interested in comparing glycopeptide profiles from one sample to another, or the 
focus may be to compare the quantities of the individual glycoform abundances on a 
particular glycoprotein.  For instance, Kondo et. al. was interested in comparing the 
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glycopeptide profiles of sialylated glycopeptides between healthy and antiphospholipid 
syndrome patients in β2-glycoprotein 1.113  These researchers purified their protein with 
an antibody, digested it, conducted an additional purification at the glycopeptide level 
using solid phase extraction, and probed the glycopeptides using MALDI- (Matrix 
Assisted Laser Desorption Ionization) and ESI- (Electrospray Ionization) MS.113  
Thaysen-Anderson et. al. was interested in quantifying all the different glycoform 
abundances at key glycosylation sites on several example proteins, not comparing how 
glycosylation a given protein can change during a disease state.111  The label-free 
studies he carried out were done on model proteins such as RNase B, IgG, and fetuin.  
While the proteins were available in purified form, the glycopeptides still needed to be 
enriched from nonglycosylated species after tryptic digestion.  To achieve efficient 
sample preparation, the authors compared a series of purification methods and 
analyzed data by MALDI-MS, and validation of their results was accomplished by 
performing label-free quantitation on the released glycans.111  
Additional examples of researchers profiling the glycosylation on a key protein or 
set of proteins are also available. Ivancic et. al. analyzed α1-acid glycoprotein for 
differences in N-linked glycosylation branching (ie. biantennary, triantennary, or 
tetraantennary) by summing the extracted ion chromatographic peak areas for each 
branching type and comparing the percent of each branching type between two gene 
products of α1-acid glycoprotein.114  In this work, the protein was first isolated by affinity 
chromatography and the de-sialylated protein was proteolyzed and subjected to reverse 
phase HPLC separation, prior to ESI-MS analysis.  
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Tajiri et. al. was interested in calculating a ratio of fucosylated to de-fucosylated 
glycopeptides to determine the extent of fucosylation at specific glycosylation sites in 
glycoproteins.112  In those studies, different antibody-purified proteins were digested, 
and the glycopeptides were subjected to a glycopeptide enrichment protocol using 
sepharose.  Rebecchi et al also used the sepharose enrichment method in developing a 
label-free glycopeptide-based quantitation method that can differentiate between 
glycosylation changes and changes in protein abundance in ESI-MS data.68  This 
method bridged the gap between studies that determine protein up and down regulation 
vs. analyses to quantify glycosylation changes.68  Selman et. al. analyzed the 
glycopeptide profiles of their glycoprotein of interest (IgG) for a multitude of clinical 
samples.67  In this case, isolated IgG glycopeptides were subjected to a rapid SPE 
purification, and MALDI-MS was used to profile IgG from 62 human serum samples. 
Glycopeptides were quantified based on relative intensity of each of the peaks.37  
Other research in glycoproteomics is to use glycopeptide strategies in 
conjunction with other techniques. Wagner-Rousset et. al. developed a three-tiered 
approach to studying glycoproteins; they analyzed intact protein, released glycans, and 
glycopeptides.117  To quantify glycopeptides, the relative intensities of the glycoforms 
present on the glycopeptides were compared among samples.117  Wada et. al. 
conducted a multi-laboratory study to compare reproducibility in glycoproteomics 
methods across different instrumentation, researchers, and sample preparation 
procedures.  In addition to quantifying glycans released from glycopeptides, a 
glycopeptide-based relative quantification approach was adopted by two laboratories; in 
these cases, the quantitative results were consistent with the glycan released studies.102   
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Finally, while the main thrust of glycoproteomic quantitation at the glycopeptide 
level is focused on the analysis of glycoforms comprising a single, purified protein; a few 
reports demonstrate the intriguing possibility of performing the same analysis on a 
larger sample set.  For example, Uematsu and coworkers were able to compare high-
mannose-containing glycopeptides from a variety of proteins isolated from murine 
dermis and epidermis.115  A lectin affinity selection using a ConA-agarose column 
(which selects for high mannose glycans) simplified the sample complexity, and peak 
intensities from MALDI TOF/TOF were used to quantify differences between the dermal 
and epidermal samples.  In the MALDI-TOF-TOF experiments, high resolution MS/MS 
data were used to identify the peptide.115  
Similarly, glycopeptides from complex protein mixtures were quantified by LC-
ESI-MS, using peak areas of the ions of interest by Ding and coworkers.71  When 
working with even larger protein mixtures, significant effort must be placed on identifying 
the glycopeptide compositions.  With ESI-MS data, identification of the protein from 
which the glycopeptide originates is possible, if MS3 data of the unglycosylated peptide 
is obtainable.71   
1.4 Structural/stability analysis of glycoproteins 
While mass spectrometry is very useful for protein identification and relative 
quantification, especially for proteins containing post-translational modifications, it is 
difficult to use mass spectrometry to assess protein structure and stability.  There has 
been some success in using chemical cross-linking,118 hydrogen-deuterium 
exchange,119, 120 and limited proteolysis121 for determining proximity of certain protein 
regions and exposed residues by mass spectrometry; however, these approaches 
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cannot match the structural detail determined by techniques like nuclear magnetic 
resonance (NMR) spectroscopy and X-ray crystallography.122, 123  Unfortunately, both 
NMR and X-ray crystallography require large amounts of protein in a very pure state.119-
121, 124  An alternative approach for structural analysis of glycoproteins, which has an 
added benefit of being able to also assess protein thermal stability is circular dichroism 
(CD) spectroscopy.124  CD spectroscopy would be classified as somewhere between 
mass spectrometry and NMR for structural analysis of proteins because CD 
spectroscopy determines the level of secondary structure present rather than either 
primary amino acid sequence (mass spectrometry) or tertiary structure (NMR).   
1.4.1 Circular dichroism spectroscopy 
CD spectroscopy works by shining left and right circularly polarized light through 
a protein sample, where changes in the absorbance of the light are assessed, in terms 
of ellipticity, for the secondary structural elements of the protein, such as alpha helices 
and beta sheets.124, 125  A protein’s structural elements absorb the left and right 
circularly polarized light differently.125  Measuring the changes in the absorbance of the 
light at different wavelengths in the far UV region helps to determine the percentages of 
alpha helices and beta sheets present in a protein sample.125, 126  Thermal stability 
studies can also be performed on a CD instrument, as well.  The change in ellipticity is 
monitored at one wavelength as the temperature of the protein solution is linearly 
increased, causing the protein to slowly unfold.127  Melt plots typically can be fitted to a 
sigmoidal curve where the inflection point, or melt temperature (Tm), is considered the 
point where half the protein is folded and the other half unfolded.128  The higher the Tm, 
the more stable (or resistant to unfolding) the protein is considered.   
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1.5 Concluding remarks 
Mass spectrometry is a versatile tool for identification and quantitation of 
glycoproteins where both large-scale glycoproteomics studies containing thousands of 
proteins and glycoproteins can be analyzed, as well as the analysis of a single 
glycoprotein, such as in the development of pharmaceuticals.  High performance liquid 
chromatography mass spectrometry utilizing high resolution mass spectrometers (FT-
ICR and orbitrap MS) for MS analysis combined with powerful tandem mass 
spectrometry instruments (performed in linear ion traps) make it possible to separate 
and unambiguously detect many peptides present in proteins, including those 
containing post-translational modifications, such as glycosylated peptides, in a single 
LC-MS run.  The biological functions of glycoproteins, as well as their increasing 
importance in disease progression and pharmaceutical development, make 
identification and quantitation of glycoproteins necessary for disease prevention and 
overall health.  Developing methods aimed at improving detection of glycoproteins are 
needed, as well as innovative strategies for relative quantitation of glycoproteins, for 
detection of glycosylation and glycoprotein concentration changes.  The work described 
in this dissertation sought to fill both voids.  Chapters 2 and 3 focus on improvement of 
the protease digestion procedure, which can be a bottleneck in the analysis of 
glycoproteins.  Chapter 2 describes the method development steps and Chapter 3 
applies the optimized digestion protocol for MS analysis on a novel glycoprotein.  
Chapter 4 illustrates a new mass spectrometric method for relative quantitation of 
glycoproteins.  Chapter 5 uses circular dichroism spectroscopy as a pre-screening 
method to assess changes in glycoprotein structure and stability upon deglycosylation. 
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1.6 Summary of subsequent chapters 
Chapter 2 discusses a systematic approach for optimizing the protease digestion 
protocol on soluble proteins as a preparatory step before mass spectrometric analysis.  
As recombinant proteins are increasingly utilized for vaccine, pharmaceutical, and 
research development, improved methodologies ensuring the characterization of post-
translational modifications (PTMs) are needed.  Typically, proteins prepared for PTM 
analysis are proteolytically digested and analyzed by mass spectrometry.  To assure full 
coverage of the PTMs on a protein, one must obtain complete sequence coverage of 
the protein, which is often quite challenging.  The objective of the research described 
here is to design a protocol that maximizes protein sequence coverage and enables 
detection of post-translational modifications, specifically N-linked glycosylation.  To 
achieve this objective, a high efficiency proteolytic digest protocol using trypsin was 
designed by comparing the relative merits of denaturing agents (urea and RapigestTM 
SF), reducing agents (dithiothreitol or DTT, and tris(2-carboxylethyl)phosphine or 
TCEP), and various concentrations of alkylating agent (iodoacetamide or IAA).  After 
analysis of human apo-transferrin using various protease digestion protocols, ideal 
conditions were determined to contain 6 M urea for denaturation, 5 mM TCEP for 
reduction, 10 mM IAA for alkylation, and 10 mM DTT, to quench excess IAA before the 
addition of trypsin.  These digestion conditions were specifically designed for PTM 
analysis of recombinant protein therapeutics and can be widely implemented in 
biopharmaceutical analysis. 
Chapter 3 applies the protease digestion approach described in Chapter 2 to a 
biologically relevant protein, human lysyl oxidase-like 2 (hLOXL2) glycoprotein, which 
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has been expressed for the first time in Drosophila S2 cells.  As hLOXL2 has been 
shown to be involved in the metastasis of several different types of cancer, there is 
strong interest in the development of hLOXL2 as a therapeutic drug for those who have 
a deficiency of the protein.  Experimental evidence shows that hLOXL2 contains 2 N-
linked glycoslation sites, 8 disulfide bonds, and a lysyl-tyrosol cross-link that is 
conserved across all LOX and LOX-like proteins.  This class of proteins, though studied 
extensively, is difficult to isolate as well as to express.  Thus, there are no prior studies 
where the LOX and LOX-like proteins have been completely mapped by mass 
spectrometry.  Through mass spectrometric analysis, high protein sequence coverage 
was achieved (> 90 %); the glycosylation was detected and was determined to be 
consistent with the typical glycosylation profile for the cell line used.  Finally, the cross-
link was identified as partially intact.  In order to obtain all the needed information on 
hLOXL2 by mass spectrometry, two different mass spectrometers were used.  The first 
was an ESI-LTQ-FTICRMS, where a combination of high resolution MS and MS/MS 
spectra yielded high protein sequence coverage, but only glycopeptides from  one of the 
two glycosylation sites were detected and the intact lysyl-tyrosol cross link was not 
found in the MS or MS/MS data.  The second instrument utilized was an ESI-LTQ Velos 
MS, which provides low resolution MS data, but improved MS/MS sensitivity compared 
to the LTQ MS.  By using the ESI-LTQ Velos MS, glycopeptides were detected at both 
glycosylation sites; additionally, the intact lysyl-tyrosol cross link was detected as well.  
The high success rate on the analysis of hLOXL2 validated the protease digestion 
procedure that was optimized in Chapter 2.  These experiments illustrate the 
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importance for novel method development in protease digestion protocols that aim to 
prepare soluble glycoproteins for MS analysis. 
Chapter 4 describes a method for quantifying glycosylation changes on 
glycoproteins.  This novel method uses MS data of glycopeptides to analyze 
glycosylation profiles, and several quality control tests were done to demonstrate the 
method is reproducible, robust, applicable to different types of glycoproteins, and 
tolerant of instrumental variability during ionization of the analytes.  This method is 
unique in that it is the first label-free quantitative method specifically designed for 
glycopeptide analysis.  It can be used to monitor changes in glycosylation in a 
glycosylation site-specific manner on a single glycoprotein, or it can be used to quantify 
glycosylation in a glycoprotein mixture.  During mixture analysis, the method can 
discriminate between changes in glycosylation of a given protein, and changes in the 
glycoprotein’s concentration in the mixture.  This method is useful for quantitative 
analyses in biochemical studies of glycoproteins, where changes in glycosylation 
composition can be linked to functional differences; it could also be implemented in the 
pharmaceutical industry, where glycosylation profiles of glycoprotein-based therapeutics 
must be quantified.  Finally, quantification of glycopeptides is an important aspect of 
glycopeptide-based biomarker discovery, and our quantitative approach could be a 
valuable asset to this field as well. 
Chapter 5 describes an approach for using circular dichroism (CD) spectroscopy 
to detect changes in structure and thermal stability on high mannose containing N-
linked glycoproteins after glycan removal.  This work is potentially useful as a pre-
screening technique for identifying glycoproteins that do not require glycosylation once 
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a protein is properly folded, thereby allowing protein expression to be performed in cell 
lines, such as yeast and insect cells.  These cell lines produce proteins with the yields 
necessary for mass production of therapeutic protein drugs, but do not produce the 
human-like N-linked glycosylation necessary for therapeutic affects in the body.  
Glycoproteins that “pass” the CD spectroscopy test (i. e. no measurable changes in 
structure and thermal stability are detected upon deglycosylation) can then be targeted 
for further functional assays, to confirm that deglycosylation does not affect protein 
function.  This approach for screening the effects of glycosylation was first implemented 
on a model glycoprotein (ribonuclease B) containing one N-linked glycosylation site with 
high mannose type glycans.  CD structure and thermal stability scans were taken before 
and after deglycosylation with the enzyme Peptide-N-glycosidase F.  Mass 
spectrometric analysis was also performed to ensure that the deglycosylation reaction 
went to completion.  CD secondary structural scans on ribonuclease B resulted in 
identical percentages for α-helical and β-sheet content and the calculated Tm for thermal 
stability was within 0.2 °C for the glycosylated and deglycosylated forms of ribonuclease 
B.  In summary, these results indicate that little or no change was observed in the 
structure and stability upon deglycosylation.  This procedure was then applied to a 
potential therapeutic glycoprotein, human lysyl oxidase-like 2 (hLOXL2).  Mass 
spectrometric analysis of hLOXL2 indicated that the deglycosylation reaction with 
PNGase F went to completion, and similarly to ribonuclease B, there was essentially no 
change in structure detected by CD spectroscopy upon deglycosylation of hLOXL2.  
Thermal stability analysis was inconclusive, however, because rather than unfolding, 
hLOXL2 precipitated out of solution as the temperature was increased.   
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DETERMINATION OF AN IDEAL PROTEASE DIGESTION PROCEDURE 




Recombinant proteins are designed and produced for a variety of reasons, most 
notably for use as therapeutic agents1-3 and vaccine candidates.4-8  Utilizing 
recombinant DNA technology and genetic engineering to produce a wide-range of 
proteins has been shown to be beneficial in the development of various 
pharmaceuticals, as demonstrated by pharmacological studies involving interferons,2 
reproductive hormones,9 and monoclonal antibodies.1, 10  More recently, the use of 
recombinant proteins has focused on the development of potential biopharmaceutical 
protein drugs that contain novel post-translational modifications (PTMs), in an effort to 
alter the solubility, efficacy, half-life, and in-vivo clearance rate in comparison to the 
characteristics of the corresponding native protein sequences.1, 10, 11  For potential 
protein pharmaceuticals, full characterization including PTMs is critical in the drug 
development process. 
Mass spectrometry (MS) is an important tool for protein identification10, 12 and 
quantification,11, 13-15 and is especially powerful in the analysis of proteins.  MS is 
perhaps the most commonly utilized technique for primary sequence characterization of 
recombinant proteins, as well as for the detection of PTMs.2, 16  Common preparatory 
steps leading to MS involving proteins (recombinant or otherwise) include a protease 
digestion procedure, where the primary protein sequence is cleaved into peptides prior 
to MS analysis.  The peptides formed from digestion typically retain their PTMs, thereby 
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allowing MS and tandem MS experiments to detect these modifications to be used to 
detect these modifications, and determine the PTM location on the protein.17-18  For 
detection of all the different PTMs present in proteins, it is advantageous to achieve full 
protein sequence coverage.19  Therefore, efficient protease digestions are crucial in 
order to achieve accurate characterization and full detection for peptides containing 
PTMs.3, 20   
In order to develop optimized methods for mass spectrometric analysis of 
peptides and PTMs on proteins, previous work has focused on several different stages 
of the protein preparation process ranging from evaluation of different types of mass 
spectrometers21, 22 or separation methods,20 to comparing specific aspects of a protease 
digestion procedure.23-26  Inefficient protease digestion procedures will inevitably result 
in poor mass spectrometry data, no matter how efficient the separation methods or 
mass spectrometer parameters are.23, 25-28  In many instances, if a protein is not 
properly unfolded prior to addition of protease, the protease will not efficiently cleave the 
protein, and therefore, MS data interpretation suffers because several peptides, 
consisting of different degrees of enzymatic mis-cleavage, will be diluted over multiple 
m/z values, and those peptides that are difficult to ionize will not be detected, leading to 
lower protein sequence coverage.10, 19, 23, 27 
Proteolytic digestion methods consist of several procedural steps prior to the 
addition of an enzyme to cleave a protein into peptides, including: denaturation, or 
unfolding of protein(s), reduction of disulfide bonds, and subsequent alkylation, or 
“capping,” of reduced cysteine residues.  Previous studies have focused on each of the 
individual steps in the protease digestion process, and hence much of the previous 
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optimization research has concentrated on the individual parameters, such as 
denaturation.24, 25, 27, 29, 30  Additionally, most of the recent emphasis has centered on the 
MS analysis of membrane proteins27, 29 and cellular proteome elucidation.24, 25  Analysis 
of cellular proteomes incorporates numerous membrane-bound proteins; thus, it was no 
surprise that published experimental findings were favorable toward MS friendly 
detergents, such as RapigestTM SF, as detergents are known to aid in the solubilization 
of membrane-bound proteins.29  It is unknown whether these conditions would be 
optimal for recombinantly expressed proteins, which are typically secreted, post-
translationally modified, and not membrane-bound.   
Due to the common presence of disulfide bonds present in many proteins 
analyzed by MS, research also has focused on optimizing conditions for reduction30, 31 
and alkylation.23, 32, 33  When reduction and alkylation are incomplete, a lower signal to 
noise ratio is often seen, as peaks may be present in the MS data that correspond to 
both derivatized and underivatized peptides.15  Thus, peptides with already low 
ionization efficiencies, such as glycosylated peptides, may not be detected because 
splitting peptide ions over multiple m/z values can result in ion abundance too low for 
MS detection.15  Moreover, over alkylation of peptides, or alkylation of the N-terminus or 
other amino acid side chains besides cysteine, can also occur when alkylation is 
allowed to incubate with the sample long periods of time, such as when alkylating agent 
is not removed during the protease procedural step.34  Therefore, optimization of 
reduction and alkylation conditions is also essential to maximize protein sequence 
coverage by MS.  
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The work described herein focuses on designing an ideal protease digestion 
protocol for readily soluble proteins containing both disulfide bonds and N-linked 
glycosylation, with a specific goal of  identifying reaction conditions yielding the highest 
protein sequence coverage, as well as effective detection of N-linked glycosylation.  
Multiple parameters in the protease digestion process were assessed by developing 
several different reaction conditions on a model protein for determination of the most 
optimal digestion strategy.   
2.2 Experimental 
2.2.1 Materials and Reagents   
Human apo-transferrin (transferrin), urea, tris(2-carboxyethyl)phosphine (TCEP), 
dithiothreitol (DTT), iodoacetamide (IAA), hydrochloric acid, acetic acid, and formic acid 
were purchased from Sigma (St. Louis, MO).  Ammonium bicarbonate (NH4HCO3) was 
purchased from Fluka (Milwaukee, WI). HPLC grade acetonitrile (CH3CN) was 
purchased from Fisher Scientific (Fair Lawn, NJ). RapiGestTM SF was purchased from 
Waters Corporation (Milford, MA).  PNGase F from Flavobacterium meningosepticum 
was purchased from New England BioLabs (Ipswich, MA).  Sequencing Grade Modified 
Trypsin was purchased from Promega (Madison, WI).  Ultrapure water was obtained 
from an in-house Millipore Direct-Q® UV 3 system (Billerica, MA) with a resistance 
greater than 18 MΩ.   
2.2.2 Glycoprotein Protease Digestion Denatured with RapiGestTM SF  
Human apo-transferrin (~ 10 mg/mL) was dissolved in 0.1% RapiGestTM SF 
containing 50 mM NH4HCO3, pH 7.8 buffer.  For reduction of disulfide bonds, either 
dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP) was added.  Table 1 shows 
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the concentrations and type of reducing agent added for each of the 7 different reaction 
conditions. Samples were incubated for 45 min. at 60 °C.  Iodoacetamide (IAA) was 
added as the alkylating agent for 60 min. at room temperature in the dark.  As shown in 
Table 1, reaction condition 3 contained a step where DTT was added to quench the 
alkylation reaction after IAA had incubated with the protein samples for 1 hr. in the dark.  
Trypsin was added at a 1:30 (w/w) enzyme:protein ratio, and all samples were 
incubated at 37 °C for 18 hrs.  HCl was added to a final concentration of 50 mM to stop 
the tryptic digestion, as well as to provide an acidic solution for RapiGestTM SF 
precipitation.  Samples were re-incubated at 37 °C for an additional 45 min., then 
centrifuged to pellet out RapiGestTM SF. The supernatant was removed and stored at -
20 °C until analysis with mass spectrometry. 
 











#1 0.1% RapiGestTM SF   5 mM DTT 15 mM IAA  
#2 6 M Urea   5 mM DTT 15 mM IAA  
#3 0.1% RapiGestTM SF 10 mM DTT 15 mM IAA 20 mM DTT 
#4 0.1% RapiGestTM SF   5 mM TCEP 10 mM IAA  
#5 6 M Urea 10 mM DTT 15 mM IAA 20 mM DTT 
#6 6 M Urea   5 mM TCEP 10 mM IAA  
#7 6 M Urea   5 mM TCEP 10 mM IAA 10 mM DTT 
 
 
2.2.3 Glycoprotein Protease Digestion Denatured with urea  
Urea (6 M) was added to transferrin (~ 10 mg/mL), which had been dissolved in 
50 mM NH4HCO3, pH 7.8.  DTT or TCEP was added to reduce the disulfide bonds (see 
Table 1), and samples were incubated at room temperature for 1 hr before IAA was 
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added to alkylate Cys residues by incubation in the dark for 1 hr.  Reaction conditions 5 
and 7 contained an additional step where DTT was added to quench the alkylation 
reaction after IAA had been allowed to incubate in the dark for 1 hr.  The NH4HCO3 
buffer was added to dilute the urea concentration to 1 M before the addition of trypsin, 
at a 1:30 (w/w) enzyme:protein ratio.  Samples were then incubated at 37 °C for 18 hrs.  
To stop the trypsin reaction, 1 µL acetic acid was added per 100 µL of solution before 
storing samples at -20 °C until ready for mass spectrometry. 
2.2.4 Liquid chromatography/mass spectrometry 
The tryptic digest samples (5 µL, ~ 15 µg) were injected onto a reversed phase 
(C18) column {300 µm i.d. x 5 cm, 3 µm particle size, CVC MicroTech, (Fontana, CA)} 
using a Dionex UltiMate capillary HPLC system (Sunnyvale, CA) containing a FAMOS 
well plate autosampler.  The HPLC system was connected to an ESI-LIT-FTICRMS 
{electrospray ionization – linear ion trap – Fourier transform ion cyclotron resonance 
mass spectrometer, ThermoScientific (San Jose, CA)} containing a 7 Tesla actively 
shielded magnet.  Mobile phase solvents A and B were composed of H2O and CH3CN, 
respectively, where both solvents contained 0.1 % formic acid.  To elute peptides from 
the column, the solvent conditions were held initially for 5 min at 5 % B, linearly 
increased to 40 % B over 50 min, further increased to 90 % B in 10 min, then held at 90 
% B for 10 min, and lastly the column was re-equilibrated before the next injection.  To 
ensure that no sample carryover was detected in the MS data, a 30 min wash followed 
by a blank injection was implemented between each sample run.  The mass 
spectrometer was set to the following parameters for all samples: ESI source voltage 
was 2.8 kV, capillary voltage offset was 47 V, capillary temperature was 200 °C, FT-ICR 
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resolution was set to 25,000 for m/z 400, and MS/MS data were collected in a data 
dependent manner by selecting the 5 most intense ions in an FT-ICR MS1 scan for 
collision induced dissociation (CID), where a collision energy of 30 % and a dynamic 
exclusion window of 3 min was utilized. 
2.2.5 Data analysis 
Peptides were analyzed with Mascot (Matrix Science, London, U.K., version 
2.2.04), as well as confirmed manually.  Peak lists were extracted from raw files using 
BioWorks Browser (ThermoScientific, Version 3.5).  The following parameters were 
searched in the DTA files: 1) enzyme, trypsin; 2) up to 2 missed cleavages; 3) fixed 
modification, Cysteine carbamidomethyl; 4) variable modifications: methionine 
oxidation, carbamyl, N-terminal carbamidomethyl; 5) peptides tolerance, 0.8 Da; and 6) 
MS/MS tolerance, 0.4 Da.  If searching for under, or incomplete, alkylation of Cys 
residues, then the fixed modification of carbamidomethyl was not added to the 
parameters searched. The database searched for both transferrin and hLOXL2 was 
SwissProt 2010, taxomony Mammalia.  All peptides identified from Mascot were 
manually checked to corroborate the presence of b and y fragmentation ions in the 
MS/MS data.  Some peptides, and all glycopeptides, could not be detected using 
Mascot.  In these cases, manual interpretation of the MS1 and MS/MS data was done to 
identify peptides and glycopeptides by their characteristic fragmentation patterns (b and 
y ions for peptides, and losses of sugar residues for glycopeptides).  To be considered 
as a detected peptide through manual inspection, two criteria must be met: MS/MS data 
illustrating appropriate fragmentation was required, and the monoisotopic peak present 
in the mass spectrum had to be within 20 ppm mass error. 
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2.3 Results and discussion 
The goal of the study described herein is to determine ideally suited reaction 
conditions for proteolytic digestion of recombinant proteins and glycoproteins.  Protease 
digestion protocols include denaturation (unfolding) of a protein, reduction and alkylation 
of Cys residues (when present), and addition of a proteolytic enzyme to cleave a 
protein(s) into peptides.  It is imperative to have an effective digestion method when 
performing mass spectrometry experiments on peptides, especially in those cases when 
analyzing for post-translational modifications and/or characterizing novel proteins, as 
inefficient protein digests will inevitably lead to poor MS data.  To achieve the 
objectives, various reaction conditions are tested on a model protein, so that the optimal 
protein digest condition could be identified.  Human apo-transferrin (transferrin) was 
chosen as a model glycoprotein for the initial testing of different digestion procedures 
because transferrin possesses a high number of co- and post-translational 
modifications, including 19 disulfide bonds and two N-linked glycosylation sites.  Figure 
1 shows the amino acid sequence for transferrin.  
2.3.1 Survey of various protease digestion conditions 
Six different reaction conditions (Table 1) were initially tested on transferrin and 
the resulting MS and MS/MS data was assessed for the detection of peptides.  The 
different reaction conditions chosen allowed for the comparison of two different 
denaturants, RapiGestTM SF and urea, as well as the reducing agents, DTT and TCEP, 
and various concentrations of the alkylating agent (IAA).  Additionally, the necessity of 
adding an extra procedural step where DTT was added to quench the excess IAA, 
preventing unwanted side reactions and complications in MS data analysis, was 
 68 
investigated. In order to systematically compare 2 different denaturants concomitantly 
with comparing 2 different reductants, certain sets of conditions only differ in the 
denaturant used, such as Conditions 1 and 2 (see Table 1) where the rest of the 
digestion parameters (reducing agent type and concentration and alkylating agent 
concentration) were kept the same. 
 
 
Figure 1. Amino acid sequence of human apo-transferrin.  Blue text indicates the signal peptide.  Green 
text signifies amino acids that were detected using the seventh set of digestion conditions (See Table 1).  
Black text illustrates amino acids that were not detected using these conditions.  Red text shows Cys 
residues that were not detected. Brown text highlights N-linked glycosylation sites. 
 
 
In addition to simply detecting transferrin peptides in the MS and MS/MS data, 
other factors governing digestion efficiency were also assessed, including: 1) complete 
alkylation (or under alkylation) of the Cys residues, 2) alkylation on the N-terminus of 
peptides (over alkylation), and 3) incomplete detection of glycans.  MS1 and MS/MS 
analysis was performed to evaluate these factors for each of the seven different 
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reaction conditions (see Table 1) in an effort to determine optimal protease digestion 
conditions for transferrin. 
2.3.2 MS data analysis of peptides and criteria chosen to compare the different 
digestion conditions  
One of the key goals in this work was to obtain high sequence coverage on the 
proteins that were analyzed, because the greater the sequence coverage of a protein, 
the more optimal the digestion conditions.  Additionally, because reduction and 
alkylation were also being evaluated, it was critical to determine the extent of alkylation 
in the peptides that were analyzed, because the chosen optimal conditions should have 
complete alkylation of Cys residues without detection of over alkylation on the N-
terminus of peptides.  Thus, each peptide in the MS data needed to be searched for a 
fully alkylated peptide peak (when Cys residues were present), peaks corresponding to 
peptides with incomplete alkylation of Cys residues, and peaks containing N-terminal 
alkylation for all peptides.  The proteins being analyzed in this study are quite large, 
especially transferrin (~80 kDa); so there were numerous predicted peptides that 
needed to be searched for in the data.  Mascot was chosen to aid in MS data analysis 
to help reduce the amount of time needed to search for all the predicted peptide peaks.  
While Mascot was useful for detecting the peptides present in high abundance and 
minimizing the analysis time in identifying peptides from each of the different reaction 
conditions tested, it was not an all-inclusive solution to the data analysis problem.  Upon 
manual inspection of the Mascot results, both false positives and false negatives were 
detected, especially for peptides that were present in low abundance in the MS data.  
False positives consisted of peptides that Mascot considered a “hit” for the MS/MS data, 
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however, the MS1 peak from the high resolution data was not sufficient to be considered 
a correct match (i.e. the MS1 monoisotopic peak was > 20 ppm from the calculated m/z 
or an insufficient isotopic distribution was present and no monoisotopic peak could be 
confirmed).  False negatives were peptides that Mascot did not detect, however, upon 
manual inspection of the MS and MS/MS data the peptides were identified.  In other 
words, the monoisotopic peak was present at < 20 ppm mass error; the charge state 
was correct, and MS/MS data clearly supported the assignment.  Therefore, all the 
Mascot results were manually validated.   
Additionally, there were cases where Mascot could not be used to search for 
predicted peptides, specifically when searching the MS data for glycosylated peptides 
as well as peptides with more than one Cys, where one of the two Cys were alkylated.  
For detection of peptides not in the Mascot results, the LC-MS chromatogram was 
searched in 1 min increments for MS1 peaks within 20 ppm mass error of a given 
peptide.  If there was a match, then the MS/MS data was further searched to confirm 
the identity of the MS1 peak.  Figure 2a shows an example LC chromatogram from 
condition 3 in Table 1. The highlighted region from 41-42 min corresponds to the 
retention time averaged for the high resolution mass spectrum shown in Figure 2b.  The 
MS/MS spectrum in Figure 2c resulted from the circled peak labeled in the high 
resolution spectrum (Figure 2b).   
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Figure 2. Representative human apo-transferrin data from condition 3 (See Table 1).  (A) Total ion 
chromatogram. Highlighted in red is the region (41-42 min.) where the MS1 in (B) is shown. (B) The 2 
labeled peptides illustrate both the fully and non-alkylated peptide SAGWNIPIGLLYCDLPEPR. The peak 
that is circled in red is the m/z where MS/MS was acquired.  Additional peaks labeled with numbers alone 
indicate other detected human apo-transferrin peptides.  The * indicates the alkylated Cys residue.  (C) 
MS/MS of the non-alkylated SAGWNIPIGLLYCDLPEPR with a retention time of 41.55 min.  
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These particular MS and MS/MS spectra correspond to a peptide that was not 
alkylated, indicating that the alkylation reaction was incomplete in this case. Thus, as 
shown in Figure 2b, the peptide is diluted between the fully alkylated and the non-
alkylated form.  Fortunately, this particular peptide happened to have a strong enough 
ionization efficiency to detect both the alkylated and non-alkylated forms.  However, if 
the MS signal for the fully alkylated peptide were near the limit of detection, neither of 
these peaks would be detected in the MS/MS data, leading to a lower protein sequence 
coverage. 
2.3.3 Comparison of denaturing and reducing agents 
The most common denaturing agents available, urea (a chaotropic agent) and 
RapigestTM SF (a detergent), were chosen to compare for protease digestion 
optimization, because they have different chemical properties and unique 
characteristics, and thus have different mechanisms by which proteins are unfolded.35, 36  
Chaotropic agents have a high capacity for forming hydrogen bonds; thus these species 
compete with the protein’s intramolecular forces, ultimately disrupting those forces and 
causing the protein to unfold.  Due to the strong denaturing behavior of chaotropic 
agents, it is necessary to dilute or remove them prior to adding protease, as proteolytic 
activity could be affected.24, 35, 36  Detergents aid in solubilizing and denaturing proteins 
by adding a degree of hydrophobicity to the solution that allows the hydrophobic regions 
of the protein to interact with the solution, and thus unfold.35, 36  Unfortunately, most 
detergents are incompatible with mass spectrometry.  Even “compatible” detergents like 
the acid labile RapiGestTM SF must be removed from the digestion solution prior to 
mass spectrometry by precipitating out the surfactant, which can in turn cause 
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hydrophobic peptides to precipitate out as well.24  As shown in Table 2, urea is clearly 
the optimal denaturing agent for the model protein used in this study.  In three out of the 
four reaction conditions where urea was used to denature transferrin, high sequence 
coverage was obtained.  As shown in Table 2, the only reaction condition where a urea 
denatured sample did not achieve greater sequence coverage than samples utilizing 
RapigestTM SF for denaturation was condition 2.  The analogous reaction condition for 
condition 2 was condition 1, where the type and concentration of reducing agent, as well 
as concentration of alkylating agent were the same, and only the type of denaturing 
agent was different.  Both of these analogous reaction conditions performed poorly and 
had the lowest sequence coverage compared to all other the reaction conditions tested.  
Therefore, it was not necessarily that urea did not perform well in condition 2 (it still 
outperformed condition 1 where RapigestTM SF was utilized for denaturation), but most 
likely a poor combination of reducing and alkylating agents led to the poor sequence 
coverage result in condition 2. 
 
 
Table 2. MS/MS analysis on transferrin peptides for seven different protein digestion reaction conditions. 
 
Reaction Conditions #1 #2 #3 #4 #5 #6 #7 
Protein Coverage 49.8% 66.4% 69.4% 72.5% 72.9%  80.4% 83.5% 
Cys Containing Peptides Detected 50.0% 71.1% 52.6% 73.7% 63.2% 78.9% 81.6% 
Under Alkylation Detected 0.0% 0.0% 30.0% 0.0% 0.0% 0.0% 0.0% 
Over Alkylation Detected 69.6% 48.4% 0.0% 41.7% 0.0% 17.5% 0.0% 
Type of Glycans Detected at N432 Bi Bi Bi Bi aBi Bi Bi 
Type of Glycans Detected at N630 Bi Bi Bi Bi Bi Bi Bi/bTri 




DTT and TCEP were chosen as competing reducing agents for the optimization 
study.  When disulfide bonds are present in a protein and not reduced prior to the 
addition of protease, the resulting MS data contains disulfide-bonded peptides, which in 
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turn complicates the data analysis compared to a solution of peptides in which all 
disulfide bonds have been broken.  Therefore, unless disulfide-bonded peptides are 
required for a particular analysis, proteins are typically reduced prior to protease 
digestion.  DTT is an inexpensive, common, and readily available reducing agent; 
however, TCEP has been cited in the literature in recent years to be a potentially better 
alternative to DTT, because it does not interfere with the common alkylating agent 
IAA.30, 31  DTT competes with Cys residues for IAA alkylation due to the presence of 
thiol functional groups in the structure of DTT.  TCEP also has an improved pH range, 
compared to DTT, and it is stable over a longer period of time, as DTT is known to 
degrade rapidly within a few hours when in solution.30, 31  Conversely, TCEP is an acidic 
compound and thus, more care needs to be taken in the preparation of solutions to 
which it is added.  TCEP also has been cited to produce protein backbone cleavage 
around Cys residues.37  Therefore, careful evaluation of both reducing agents was 
necessary for protease digestion optimization.  No cleavages around Cys residues 
(unless a Cys residue was next to an Arg or Lys where trypsin would be expected to 
cleave it) were observed in the MS data presented here.  As shown in Table 2, two out 
of the three reaction conditions where TCEP was used as the reducing agent, TCEP 
yielded greater sequence coverage than the reaction conditions where DTT was the 
reducing agent.  The one time where TCEP did not outperform a DTT reduced sample 
was in condition 4, where RapigestTM SF was used to denature transferrin instead of 
urea.  As already discussed above, RapigestTM SF was not determined to be an optimal 
denaturing agent.  Therefore, that particular sample of transferrin was probably not 
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completely unfolded prior to addition of TCEP, which led to TCEP ineffectively reducing 
the disulfide bonds. 
2.3.4 Under alkylation of Cys residues 
Incomplete alkylation of Cys residues may occur when a protein is not entirely 
unfolded or when disulfide bonds are inefficiently reduced, thereby rendering the 
alkylating agent inaccessible to those residues.15  The only protease digestion 
procedure where under alkylation was detected was condition 3, as shown in Table 1.  
Aside from condition 3, which is obviously not an optimal protocol, under alkylation was 
not a significant issue. 
2.3.5 Over alkylation 
Over alkylation occurs when alkylation is detected on the N-terminus of peptides, 
as opposed to being limited to Cys residues.  Although alkylating agents are most 
selective to thiol groups, amines can also become reactive when given enough 
incubation time.34  As no reagents were removed from the reaction mixtures during the 
protease digestion, there was ample time for IAA to react with the N-terminus of newly-
formed peptides that formed after cleavage by trypsin.  Indeed, the results from Table 2 
indicate that over alkylation was detected in all reaction conditions that lacked an 
additional step of adding DTT to quench alkylation of IAA, regardless of the identity of 
reducing or denaturing agent used.  Therefore, the optimal protease digestion condition 
must incorporate a step to quench IAA after alkylation. 
2.3.6 Evaluation of sequence coverage 
As described above, the main criterion used to determine the optimal protease 
digestion conditions was protein sequence coverage.  The reaction conditions listed in 
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Table 2 are shown from left to right in increasing sequence coverage.  Sequence 
coverage, however, was not the only criterion used to determine optimal reaction 
conditions.  Due to the many peptides that contained one or more Cys residues, and 
because under and over alkylation was being evaluated, the percentage of Cys-
containing peptides was also evaluated and compared to total sequence coverage.  An 
efficient trypsin digestion with proper reduction and alkylation should contain similar 
results for Cys-containing peptides compared to total sequence coverage.  As shown in 
Table 2, most of the digestion conditions did have similar values for sequence coverage 
and Cys-containing peptides, except for conditions 3 and 5, where there is an 
approximate 10 % drop in detection of Cys-containing peptides compared to sequence 
coverage, which is probably due to inefficient reduction and alkylation reactions in these 
reaction procedures. 
2.3.7 Determination of the optimal conditions 
As described above, transferrin was proteolytically digested utilizing the first 6 
reaction conditions from Table 1 and subsequently analyzed by LC-MS.  High resolution 
MS1 and MS/MS data were searched for transferrin peptides.  The results from this 
study were compiled in Table 2 where the reaction conditions are listed in order of 
lowest sequence coverage to highest sequence coverage.  As described above, it was 
determined that urea outperformed RapigestTM SF as a denaturant and TCEP 
outperformed DTT as a reducing agent.  Condition 6, which utilized both urea and 
TCEP for denaturation and reduction, respectively, was nearly optimal, except for the 
presence of several over alkylated peptides.  Upon reviewing these results, a seventh 
reaction condition was developed with the same protease digestion procedure from 
 77 
condition 6, but with an additional step after alkylation where DTT was added to quench 
unreacted IAA (see Table 1 for full digestion details).  The transferrin peptides identified 
in the MS data from the condition 7 digestion protocol are highlighted in Figure 1, with a 
complete list, including the mass error of each of the identified peptides and 
glycopeptides, compiled in Table 3.  As described in Table 2, condition 7 had the 
greatest sequence coverage, no under or over alkylation was detected.  Thus, condition 
7 was expected to be the optimal protease digestion condition. 
 
Table 3. List of human apo-transferrin peptides detected under the optimal conditions (Conditions 4 in 











WCAVSEHEATK 2 659.2983 659.2985 0.38 
SVIPSDGPSVACVK 1 1415.7197 1415.7278 5.72 
ASYLDCIR 1 997.4771 997.4789 1.80 
AIAANEADAVTLDAGLVYDAYLAPN
NLKPVVAEFYGSK 3 1318.6772 1318.6864 7.00 
EDPQTFYYAVAVVK 2 815.4116 815.4159 5.33 
KDSGFQMNQLR 2 662.3274 662.3269 0.75 
DSGFQMNQLR 1 1195.5525 1195.5559 2.84 
SAGWNIPIGLLYCDLPEPR 2 1086.0513 1086.0589 7.00 
AVANFFSGSCAPCADGTDFPQLCQ
LCPGCGCSTLNQYFGYSGAFK 3 1663.3706 1663.3918 12.75 
DGAGDVAFVK 1 978.4891 978.4930 3.99 
HSTIFENLANK 1 1273.6536 1273.6555 1.49 
ADRDQYELLCLDNTR 2 941.4416 941.4424 0.85 
DQYELLCLDNTR 2 770.3591 770.3610 2.53 
KPVDEYKDCHLAQVPSHTVVAR 3 850.4358 850.4371 1.57 
DCHLAQVPSHTVVAR 2 845.4281 845.4292 1.36 
SMGGKEDLIWELLNQAQEHFGK 2 1265.6236 1265.6341 8.34 
SMGGKEDLIWELLNQAQEHFGKDK 2 1387.1845 1387.1968 8.87 
EDLIWELLNQAQEHFGK 2 1035.5183 1035.5227 4.25 
SKEFQLFSSPHGK 2 746.3832 746.3837 0.67 
EFQLFSSPHGK 2 638.8197 638.8220 3.60 
DLLFK 1 635.3764 635.3776 1.89 
DSAHGFLK 1 874.4418 874.4449 3.55 
MYLGYEYVTAIR 2 739.8711 739.8723 1.62 
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EGTCPEAPTDECKPVK 2 909.4058 909.4064 0.66 
WCALSHHER 2 598.2749 598.2750 0.17 
LKCDEWSVNSVGK 2 761.3720 761.3740 2.69 
CDEWSVNSVGK 1 1280.5575 1280.5590 1.17 
IECVSAETTEDCIAK 2 863.3872 863.3891 2.26 
IMNGEADAMSLDGGFVYIAGK 2 1080.0111 1080.0165 5.00 
CGLVPVLAENYNK + 
a[Hex]5[HexNAc]4[NeuNAc]2 2 1841.2656 1841.2623 1.79 
SDNCEDTPEAGYFAVAVVK 2 1036.4674 1036.4744 6.75 
KSASDLTWDNLK 2 689.3541 689.3543 0.29 
TAGWNIPMGLLYNK 2 789.4110 789.4151 5.26 
FDEFFSEGCAPGSK 2 789.3325 789.3357 4.12 
LCMGSGLNLCEPNNK 2 853.8866 853.8923 6.68 
EGYYGYTGAFR 2 642.2883 642.2887 0.70 
CLVEK 1 648.3386 648.3375 1.70 
GDVAFVK 1 735.4036 735.4005 4.22 
HQTVPQNTGGKNPDPWAK 2 987.9927 987.9954 2.78 
NPDPWAK 1 827.4045 827.4043 0.24 
NLNEKDYELLCLDGTR 2 976.9728 976.9775 4.81 
DYELLCLDGTR 1 1354.6308 1354.6392 6.20 
KPVEEYANCHLAR 2 793.8908 793.8914 0.76 
QQQHLFGSNVTDCSGNFCLFR + 
a[Hex]5[HexNAc]4[NeuNAc]2 4 1180.7296 1180.7332 3.05 
QQQHLFGSNVTDCSGNFCLFR + 
a[Hex]6[HexNAc]5[NeuNAc]3 3 1792.7042 1792.7129 4.85 
DLLFR 1 663.3825 663.3842 2.56 
DLLFRDDTVCLAK 2 783.4033 783.4047 1.85 
DDTVCLAK 1 921.4346 921.4362 1.74 
YLGEEYVK 1 1000.4987 1000.5039 5.20 
KCSTSSLLEACTFR 2 830.3951 830.3975 2.89 
CSTSSLLEACTFR 2 766.3476 766.3476 0.00 
 
2.3.8 Detection and analysis of glycopeptides 
In addition to the criteria above, one key feature of an ideal digestion protocol is 
that it produces high coverage of the post-translational modifications on the protein 
being analyzed.  Therefore, in addition to checking for sequence coverage and 
alkylation state, the seven data sets were also searched for the known PTMs on 
transferrin, which contains two N-linked glycosylation sites.  For a set of reaction 
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conditions to be considered optimal, the glycopeptides detected in the transferrin MS 
data needed to encompass all the glycoforms described in the literature for this protein 
sample.  The major glycoform known to be present on transferrin is an N-linked 
biantennary sialylated complex type glycan.38  However, transferrin also has an N-linked 
triantennary sialylated complex type glycan present in lower abundance.38  Therefore, 
the MS data was searched for both biantennary and triantennary sialylated complex 
type glycopeptides in the data sets from all 7 reaction conditions.  As shown in Table 2, 
biantennary N-linked sialylated glycopeptides were detected at both glycosylation sites 
in transferrin in data sets from all 7 reaction conditions.  This was expected, since the 
biantennary glycans are the most abundant glycoforms in transferrin.38  The data set 
where the lesser abundant triantennary glycans were detected was from condition 7.  
The triantennary N-linked glycan details are listed in Table 3 with the 
QQQHLFGSNVTDCSGNFCLFR peptide portion.  The presence of the less common 
glycoform detected only in the MS data for condition 7 was further confirmation that 
condition 7 was indeed the most optimal reaction protocol.  
2.4 Concluding remarks  
Properly preparing proteins for mass spectrometric analysis through protease 
digestion is a critical process for protein identification, especially on those proteins that 
containing PTMs because many PTMs, such as glycosylation, have poor ionization 
efficiencies compared to peptides that do not contain PTMs.  Inefficient digestions will 
lead to poor MS data, thus the goal of this research was to employ a systematic 
strategy for developing an ideal protease digestion protocol for recombinantly 
expressed proteins containing post-translational modifications.  Additionally, we 
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illustrated the general applicability of our findings by using the identified conditions in 
the successful analysis of a protein that had never before been analyzed by mass 
spectrometry; therefore the developed protocol should be an efficient method for other 
soluble proteins. 
The ideal protease digestion reaction contained 6 M urea for denaturation, 5 mM 
TCEP for reduction, 10 mM IAA for alkylation, and 10 mM DTT for quenching the 
alkylation reaction.  As described in Table 2, these conditions illustrated the highest 
protein sequence coverage with no under or over alkylation detected in the MS data.  
These conditions were also the only reaction conditions where triantennary N-linked 
glycopeptides were detected in the transferrin data.  This is significant because other 
researchers have been able to detect the triantennary N-linked glycans in 
deglycosylated transferrin data.38  Therefore, these glycoforms are expected to be 
detected as glycopeptides as well.  
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MASS SPECTROMETRIC ANALYSIS OF SEQUENCE COVERAGE AND 
POST-TRANSLATIONAL MODIFICATIONS OF HUMAN LYSYL 
OXIDASE-LIKE 2 GLYCOPROTEIN EXPRESSED IN A DROSOPHILA 
CELL LINE  
 
3.1 Introduction 
Lysyl oxidase (LOX) is a secreted copper-containing amine oxidase that forms 
reactive aldehydes by oxidating the ε-amino group of lysine side chains in collagen and 
elastin.1  LOX contains a cross-linked quinone cofactor aring from a post-translational 
modification (PTM) of its lysyl and tyrosol residues, which are conserved across all LOX 
and lysyl oxidase-like (LOXL) proteins.1-7  Enzymatically, LOX has been shown to 
promote stability in the extracellular matrix (ECM) through catalysis of intra- and 
intermolecular cross-linkages that act to determine mechanical properties.1, 8-10  
Research involving lysyl oxidase and lysyl oxidase-like proteins (LOXL, LOXL2, LOXL3 
and LOXL4) has implicated that these enzymes participate in a variety of biological 
processes, including extracullular matrix stabilization, cellular growth, and 
homeostasis.1, 8-9   
Each of these enzymes share a conserved C-terminal amino acid sequence 
containing residues that form a carbonyl cofactor, copper binding site, and a cytokine 
receptor-like domain that are crucial for enzymatic activity,5-6, 11 but vary in their N-
terminal domain content.1  Much less is known about the function of the individual 
enzymes9 and their post-translational modifications (PTMs); therefore characterization 
of the protein by mass spectrometry can contribute new knowledge to the 
understanding of LOX and LOXL proteins.  
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Moreover, developing MS-based methods to characterize these proteins is also 
important because LOX family participants are attractive pharmacological targets as 
dysregulation of LOX has been found to correlate to numerous diseases and adverse 
physiological states, including cancer formation and metastasis, connective tissue 
disorders, neurodegenerative pathologies, and cardiovascular abnormalities.9, 12-15   
Specifically, LOXL2 has been shown to be involved in abnormal collagen 
deposition, tumor invasion, lymph node metastasis, and cancer progression in breast 
and ovarian cancers.4, 12-14, 16-17  As such, characterization of LOXL2 is an essential step 
in assessing its viability as a pharmacological candidate of interest as regulatory roles 
for which the quinone cofactor become further elucidated and better understood.  
The work described herein utilizes mass spectrometry for the complete 
characterization of hLOXL2 that was expressed for the first time in a Drosophila cell 
line.  For protein characterization by mass spectrometry, a protease digestion was 
performed so that the protein sequence and PTMs present in hLOXL2 could be 
detected.  To ensure an efficient protease digestion, the optimal digestion conditions 
identified from the transferrin study were used.  The full details of the transferrin study 
are described in Chapter 2.  Because hLOXL2 has not been fully analyzed by mass 
spectrometry before, full protein sequence coverage was desired, in addition to 
detection of the PTMs including glycosylation suspected at the 2 N-linked glycosylation 
consensus sequences and the intact lysyl-tyrosol cross-link.  The analysis of hLOXL2 
by mass spectrometry should prove valuable in assessing the structural details for this 




3.2.1 Materials and reagents 
Trizma® HCl, Trizma® base, tris(2-carboxyethyl)phosphine (TCEP), urea,  
ethylenediamintetraacetic acid (EDTA), dithiothreitol (DTT), iodoacetamide (IAA), acetic 
acid and formic acid were purchased form Sigma (St. Louis, MO).  HPLC grade 
acetonitrile was purchased from Fisher (Fair Lawn, NJ).  Sequencing grade modified 
trypsin was purchased from Promega (Madison, WI). Water was purified in-house with a 
Millipore Direct-Q® UV-3 system (Billerica, MA) and was only used when the resistance 
was > 18 MΩ.  A recombinant form of human lysyl oxidase-like 2 (hLOXL2) was 
prepared using and insect expression system prepared by the Mure lab at the University 
of Kansas.   
3.2.2 Protease digestion 
 Human lysyl oxidase-like 2 (hLOXL2) protein was supplied at 2 mg/mL in 100 
mM Tris, pH 8.5 in 1 mM EDTA and 150 mM NaCl.  Solid urea was added to the sample 
to a final concentration of 6 M, for protein denaturation, followed by the addition of 
TCEP, to a concentration of 5 mM, for reduction of disulfide bonds.  The sample was 
then allowed to incubate at room temperature for 1 hr.  IAA (10 mM) was added to 
alkylate the Cys residues so that refolding of the protein could not occur.  This reaction 
was allowed to proceed for 1 hr at room temperature in the dark.  The alkylation 
reaction was quenched by the addition of 10 mM DTT.  Since the urea content was too 
high for efficient trypsin digestion, the sample was diluted until the final concentration of 
urea was 1 M.  At this point trypsin was added at a 1:30 enzyme:protein ratio for 
protease digestion.  The sample was placed in a 37 °C oven for 18 hrs and stopped by 
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the addition of 1 µL acetic acid for every 100 µL of solution.  After digestion was 
complete, the sample was placed in a Labconco centrivap cold trap (Kansas City, MO) 
to concentrate the sample to ~ 3 mg/mL.  Samples were stored at -20 °C until LC-MS 
could be performed. 
3.2.3 Liquid chromatography/mass spectrometry 
3.2.3.1 Mass spectrometry on an ESI-LTQ-FTICR MS 
 The protease digestion sample, hLOXL2 (5 µL, ~15 µg), was injected onto a C18 
column (300 µm i.d., 5 cm length, and 3 µm particle size) produced by CVC Microtech 
(Fontana, CA) that was connected to a Dionex UltiMate capillary HPLC system 
(Sunnyvale, CA) containing a FAMOS well plate autosampler with an electrospray – 
linear ion trap – Fourier transform ion cyclotron resonance mass spectrometer (ESI-LTQ 
-FTICRMS), ThermoScientific (San Jose, CA) containing a 7 Tesla actively shielded 
magnet for detection.  Aqueous mobile phase consisted of 99.9 % water and 0.1 % 
formic acid (solvent A) and organic mobile phase was composed of 99.9 % acetonitrile 
and 0.1 % formic acid (solvent B).  For reversed phase separation of the peptides in 
hLOXL2, the following gradient was used: Solvent conditions were held at 5% B for 5 
min, a linear increase to 40% B in 50 min, another linear increase to 90% B in 10 min, 
held at 90% B for 10 min, and re-equilibration of the column.  Between each sample 
run, a short 30 min wash cycle and blank were run to ensure no carry over was 
detected between samples.  The ESI source was set to 2.8 kV, capillary temperature 
was 200 °C, capillary voltage offset was 47 V, and FT-ICR resolution was set to 25,000 
for m/z 400.  MS/MS data was collected in data-dependent mode where the 5 most 
intense ions from the high resolution FT-ICR MS1 scan were selected for collision 
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induced dissociation (CID) at 30% collision energy and a 3 min dynamic exclusion 
window. 
3.2.3.2 Mass spectrometry on an ESI-LTQ Velos MS 
hLOXL2 (5 µL, ~15 µg) was injected onto the same C18 column described in the 
paragraph above.  For these experiments, however, the column was connected to a 
Waters Acquity UPLC system (Milford, MA), which was directly coupled to an 
electrospray – linear ion trap mass spectrometer (ESI-LTQ Velos MS) from 
ThermoScientific (San Jose, CA). Mobile phase A and B are the same as in the above 
paragraph.  The following gradient was used for reversed phase separation of hLOXL2 
peptides:  Initial conditions were 5% B with a linear increase to 10% B in 5 min, a linear 
increase to 40% B in 45 min, a linear increase to 90 % B in 10 min, held at 90% B for 10 
min before re-equilibration of the column.  Since sample carryover is sometimes an 
issue in LC-MS analysis, a short (30 min) wash cycle and a blank run were performed 
between each sample.  For mass spectrometry, the electrospray source voltage was 3 
kV, capillary temperature was 250 °C.  For MS/MS analysis of peptides by CID (collision 
induced dissociation), a 30% collision energy was used. LC-MS/MS was set up in data 
dependent scan mode where the 5 most intense ions were chosen for MS/MS analysis 
with a 3 min dynamic exclusion window.  
3.2.4 Data analysis 
 For Mascot analysis of the MS data from the hLOXL2 sample that was run on the 
ThermoScientific ESI-LTQ-FTICRMS, the peak lists from XCalibur (Version 2.1.0.1139) 
raw files were exported into BioWorks browser (ThermoScientific, Version 3.5), which 
exported the data as a .DTA file.  The .DTA file was searched for the following 
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parameters:  1) enzyme, trypsin; 2) up to 2 missed cleavages; 3) Cysteine 
carbamidomethyl as a fixed modification (when searching for under alkylation of Cys 
residues, this parameter was removed); 4) methionine oxidation, carbamyl, and N-
terminal carbamidomethyl as variable modifications; 5) 0.8 Da peptide tolerance; and 6) 
0.4 Da MS/MS tolerance.  The MS data was searched in SwissProt 2010, taxonomy 
Mammalia, database.  All peptides detected from Mascot were also manually verified to 
ensure they met the criteria established for a detected peptide and to search for 
peptides that Mascot did not identify.  To be considered a manually detected peptide, 
two criteria must be met: MS/MS data illustrating appropriate b and y ions was required, 
and the monoisotopic peak present in the mass spectrum had to be within 20 ppm mass 
error.   
 For analysis of glycopeptides in the MS data, a manual interpretation was 
completed by two strategies.  The first strategy was to create a prediction table where 
the peptide mass from an N-linked glycosylation site was added to probable glycoforms 
specific for Drosophila cells,18 and the predicted m/z values were searched for in the 
MS/MS data. Secondly, the MS/MS data was scanned characteristic ions indicative of 
glycopeptide spectra.  For example, m/z 366 (a hexose plus an N-acetylhexosamine 
residue) is often found in glycopeptide spectra and considered a marker ion for 
glycopeptides.  Upon detection of m/z 366 and other marker ions, the spectrum was 
examined for appropriate glycan losses for compositional assignment of a glycopeptide.  
These strategies were applied for data analysis of hLOXL2 for both instruments used, 
the ESI-LTQ-FTICRMS and the ESI-LTQ Velos MS.   
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The lysyl-tyrosol cross-link was determined manually by calculating the mass of 
the cross-linked peptide with and without certain modifications, including the presence 
and absence of the phenylhydrazine tag that was added to ensure the cross-link would 
stay intact through protease digestion, up to 2 trypsin missed cleavages, and 
methionine oxidation.  The predicted m/z values calculated were searched for in the 
data for an MS/MS spectrum that contained appropriate b and y ions corresponding to 
the cross-link. 
3.3 Results and discussion 
hLOXL2 is a biologically important protein known to play a role in the 
development of several cancers,12, 14, 19 as well as a potential therapeutic.9, 17  This is 
the first example of a LOX or LOXL protein to be fully characterize by mass 
spectrometry.  The goal of this work was to use MS to obtain complete protein 
sequence coverage, as well as detect the known PTMs that occur in hLOXL2, 
specifically analysis of glycosylation present at the two potential N-linked glycosylation 
sites and detection of the lysyl-tyrosyl cross-link known to be present in all LOX and 






Figure 1. Amino acid sequence of hLOXL2 expressed in a Drosophila cell line.  Green text signifies 
amino acids that were detected by LC-MS and MS/MS analysis, as described below.  Black text illustrates 
amino acids that were not detected.  Red text shows Cys residues that were not detected. Brown text 
highlights N-linked glycosylation sites. Purple text highlights the Lys and Tyr residues involved in the 
ortho quinone cross-link. The peptide shown in blue was not detected in the high resolution ESI-LTQ-
FTICRMS data, however, it was detected as part of the lysyl-tyrosol cross-link in the low resolution ESI-
LTQ Velos MS data. 
 
3.3.1  Protein sequence coverage 
In order to obtain high protein sequence coverage for recombinant hLOXL2, a 
proteolytic digestion was performed followed by mass spectrometry.  The digestion 
conditions used for hLOXL2 were previously optimized on a model glycoprotein, 
transferrin, and described in detail in Chapter 2.  This digestion procedure utilized urea 
for denaturation, TCEP for reduction, IAA for alkylation, and DTT to quench alkylation.  
After protease digestion of hLOXL2, LC-MS and MS/MS analysis of the rendered 
peptides was performed.  The high resolution LC-MS data collected on the ESI-LTQ-
FTICR MS for the hLOXL2 digested sample was first analyzed using Mascot to aid in 
the identification of hLOXL2 peptides.  This was followed by manual validation of the 
MS and MS/MS data, as described in the experimental section.  A summary of the 
hLOXL2 amino acid residues detected is shown in Figure 1.  The overall results from 
the analysis of hLOXL2 peptides that met both the high resolution MS1 and MS/MS 
criteria are described in Table 1.  The percent protein sequence coverage was 90.8% 
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and the percent Cys-containing peptides were 93.8%. In fact, only 1 Cys residue was 
not detected in the analysis of hLOXL2.  The non-detected Cys residue is highlighted in 
red in Figure 1. This Cys residue was not expected to be detected by MS, because its 
tryptic peptide is only CR, which would have an m/z of 335, and this is outside the scan 
range used for this experiment.  Thus, a missed trypsin cleavage is necessary for CR to 
be detected.   
 
Table 1.  Summary of results from hLOXL2 peptides detected for protein sequence coverage using the 
high resolution ESI-LTQ-FTICRMS for analysis. 
 
 hLOXL2 
Protein Coverage 90.8 %  
Cys Containing Peptides Detected 93.8 % 
Under Alkylation Detected 0.0 % 
Over Alkylation Detected 0.0 % 
Major Glycorform Detected at N31 a[Hex]3[HexNAc]2[Fuc]1 
Major Glycorform Detected at N220 a[Hex]3[HexNAc]2[Fuc]1 
aHex = Hexose, HexNAc = N-acetyl hexosamine, Fuc = Fucose. 
 
All undetected peptides in the hLOXL2 data consisted of short peptides, with 6 
amino acid residues or less, found in various regions throughout the protein sequence, 
as highlighted in black in Figure 1.  Of the 9 tryptic peptides not detected by MS (see 
Figure 1), the calculated m/z for 5 of the 9 peptides fall below scan range (ie. < 500 Da); 
thus these peptides would never be detected using the scanning parameters 
implemented.  The other 4 peptides are 5 to 6 amino acid residues in length and could 
potentially be detected by MS with the scan range utilized.  However, we expect that 
these peptides have lower ionization efficiencies because of the presence of acidic 
amino acid residues (Asp and Glu) in 3 of the 4 undetected peptides, which could lower 
the ionization efficiency.  In summary, this work illustrates that high sequence coverage 
was obtained, with both MS1 and MS/MS data being available for all the detected 
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peptides.  Table 2 lists the theoretical and experimental masses of all the peptides that 
were detected in the analysis of hLOXL2.  
 
 
Table 2. List of hLOXL2 peptides detected in the ESI-LTQ-FTICR  mass spectrometer where both 
MS/MS and MS1 < 20 ppm mass error were used as parameters for a detected peptide or glycopeptide. 












SPWPGVPTSMR 2 607.8029 607.8071 6.9 
VEVLVER 1 843.4935 843.4980 5.3 
NGSLVWGMVCGQNWGIVEAMVVCR 
+ a[Hex]3[HexNAc]2[Fuc]1 + [Na]1 3 1261.8839 1261.8988 11.8 
QLGLGFASNAFQETWYWHGDVNSNK 2 1435.1701 1435.1881 12.5 
VVMSGVK 1 719.4121 719.4133 1.7 
CSGTELSLAHCR 2 695.8032 695.8062 4.3 
HDGEDVACPQGGVQYGAGVACSETA
PDLVLNAEMVQQTTYLEDRPMFMLQC
AMEENCLSASAAQTDPTTGYR 5 1583.2994 1583.3253 16.4 
FSSQIHNNGQSDFRPK 2 931.4506 931.4561 5.9 
HAWIWHDCHR 1 1417.6330 1417.6391 4.3 
HYHSMEVFTHYDLLNLNGTK + 
a[Hex]3[HexNAc]2[Fuc]1 3 1153.1799 1153.1894 8.2 
ASFCLEDTECEGDIQK 2 951.3983 951.3851 13.8 
NYECANFGDQGITMGCWDMYR 2 1294.5085 1294.5273 14.5 
HDIDCQWVDITDVPPGDYLFQVVINPN
FEVAESDYSNNIMK 3 1599.7422 1599.7617 12.2 
IWMYNCHIGGSFSEETEK 2 1094.4774 1094.4901 11.6 




3.3.2 Glycopeptide data analysis 
The CID MS/MS data of glycopeptides, including the glycopeptides from 
hLOXL2, are distinct from peptides in that, unlike peptides, glycopeptides cannot be 
identified in an automated fashion using a Mascot search, but instead must be 
characterized using other search tools.  The two strategies used to detect the 
glycopeptides present in the hLOXL2 MS data are described in the Experimental 
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section.  A glycopeptide was considered identified when two criteria were met: An 
MS/MS spectrum was needed to support the assignment, and the monoisotopic peak 
must have an m/z value of less than 20 ppm mass error compared to the calculated m/z 
in the high resolution (FTICR) MS data.   
Figure 2 is an example of a glycopeptide spectrum from one of the two 
glycosylation sites in hLOXL2.  Figure 2A shows a high resolution mass spectrum 
present where the circled peak corresponded to a glycopeptide from hLOXL2.  By 
zooming in, as shown in Figure 2A, the isotopic distribution can be seen and the 
monoisotopic m/z is determined and compared to the calculated m/z.  In this case, the 
experimental mass error is 8.2 ppm, as shown in Table 2.  Figure 2B shows the MS/MS 
data from the precursor ion circled in Figure 2A. As can be elucidated in Figure 2B, 
there are losses of monosaccharide sugar residues present in the glycopeptide data.  
These sugar losses help to identify the N-linked glycan present on a glycopeptide, a 
fucosylated N-linked glycan core ([Hex]3[HexNAc]2[Fuc]1, where Hex = hexose, 
HexNAc = N-acetylhexosamine, and Fuc = fucose).  See Figure 2B.  To confirm this 
assignment, the MS/MS data is searched for a peak corresponding to the potential 
peptide plus one hexNAc residue, called the Y1 ion.  This ion is common to many 
glycopeptide MS/MS data taken in positive ion mode.21   When a peak corresponding to 
the Y1 ion is detected in the data, and it correlates to the monosaccharide sugar losses, 
a glycopeptide is said to be identified, as shown in Figure 2B.   
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Figure 2. (A) High resolution MS1 spectrum from hLOXL2 from the retention time 38-39 min. Circled in 
red illustrates where the hLOXL2 glycopeptide ion in (B) is located in the spectrum and the zoomed in 
region shows the isotopic distribution for the hLOXL2 glyocpeptide ion where mass error can be 
calculated from the monoisotopic m/z value.  (B) hLOXL2 glycopeptide MS/MS data at m/z 1153. The 
blue squares are N-acetylhexosamines; green circles are hexoses, and the red triangle is fucose. This 
MS/MS data shows losses of glycan residues that aid in determining the glycan composition. 
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To aid in the manual analysis of the glycopeptide MS/MS data, GlycoPep DB22 
and GlycoPep ID23 were also utilized.  The predominant glycoform detected in the 
MS/MS data of hLOXL2 at both glycosylation sites was a fucosylated N-linked glycan 
core. This assignment is consistent with the fact that a fucosylated N-linked glycan core 
is known to be one of the most common glycoforms in insect cells and for proteins 
expressed in insect cell lines.18  
 Analysis of the hLOXL2 protease digestion sample run on a ThermoScientific 
ESI-LTQ-FTICRMS instrument allowed for the detection of several glycoforms for the 
HYHSMEVFTHYDLLNLNGTK glycosylation site.  However, only the most common 
fucosylated N-linked glycan core was detected at the other glycosylation site 
(NGSLVWGMVCGQNWGIVEAMVVCR).  Figure 3 shows the glycopeptides detected 
by ESI-LTQ-FTICRMS that met the criteria for glycopeptide identification: The MS/MS 
data contained appropriate glycan losses and the MS1 monoisotopic peaks were within 
20 ppm mass error.  It was concerning, however, to detect only 1 glycoform for the 
NGSLVWGMVCGQNWGIVEAMVVCR glycosylation site.  The reason for low coverage 
of heterogeneity for glycopeptides detected was not likely from the protease digestion 
process, since protein sequence coverage was very high at 90.8% (see Table 1).  
Instead, we hypothesized that the low coverage was due to the known problem of 
glycopeptides being more difficult to detect than peptides, due to their heterogeneity 
and, possibly, their lower ionization efficiency.24 
Therefore, a different mass spectrometer was chosen for analysis of hLOXL2 
glycopeptides, a ThermoScientific ESI-LTQ Velos MS.  The LTQ Velos mass analyzer 
has been shown to have advantages over the ThermoScientific LTQ regarding duty 
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cycle (~ 2x decrease in cycle time) and increased sensitivity.25  Because the LTQ Velos 
MS was a stand alone instrument and not connected to a high resolution mass 
spectrometer, such as the FTICR MS, the requirement of less than 20 ppm mass error 
in the MS1 data was removed as a criterion for glycopeptide detection. For ESI-LTQ 
Velos MS glycopeptide detection, the MS/MS spectrum with appropriate glycan losses 
must be observed, as well as the top of MS1 peak had to be within 1 Da of the 
calculated m/z.  The glycopeptides detected from hLOXL2 with the LTQ Velos MS are 
summarized in Figure 4, which shows 1 new glycoform detected for the 
NGSLVWGMVCGQNWGIVEAMVVCR glycosylation site and 3 new glycoforms for the 
HYHSMEVFTHYDLLNLNGTK glycosylation site.   
 
 
Figure 3. Compositions of the glycans detected in the hLOXL2 MS data at both N-linked glycosylation 






Figure 4.  Compositions of the glycans detected in the hLOXL2 MS data at both N-linked glycosylation 
sites with the LTQ Velos MS. 
 
 
3.3.3 Detection of the lysyl – tyrosyl cross-link 
 A unique and conserved cross-link is observed among the different types of LOX 
and LOXL proteins consisting of a lysine residue cross-linked to a tyrosine residue to 
form an ortho quinone cofactor.5-7, 20  Because this cross-link is known to occur in active 
and properly folded LOX and LOXL proteins, detecting the in-tact cross-link was one of 
the goals sought after for complete characterization of hLOXL2.  To aid in keeping the 
cross-link in-tact throughout the protease digestion procedure, the protein was 
derivatized at the cross-link site with phenylhydrazine, as circled in brown in Figure 5A.2, 
6  [This derivatization occurred as part of the sample preparation in the Mure lab and 
was not part of the experimental work described here.]  Upon successful derivatization 
of the hydrazine group, the protein solution was expected to change from a clear color 
to pale yellow, which was observed upon receiving the hLOXL2 sample.  The lysine and 
tyrosine residues involved in the cross-link are highlighted in purple in Figure 1.  
Because this lysine-tyrosine cross-link is known only to occur in LOX and LOXL 
proteins, it was not possible to utilize databases such as Mascot to aid detection of the 
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cross-linked peptide in the MS data.  After close manual inspection of the ESI-LTQ-
FTICRMS data, no evidence for the cross-linked peptide was found.  However, we 
determined that the cross-link must not be 100 % in-tact, because one of the peptides 
that should have been involved in the cross-link was detected individually (see Figure 1 
and Table 2).  As in the analysis of glycopeptides, it was determined that the abundance 
of the intact cross-linked peptide may have been too low for detection with the ESI-LTQ-
FTICRMS, so the ESI-LTQ Velos MS was employed for re-analysis of the hLOXL2 
protease digestion sample.  After inspection of the ESI-LTQ Velos MS data for the intact 
cross-link and its associated peptides, an MS/MS spectrum was found that corresponds 
to this species, as shown in Figure 5B.  Several b and y ions were detected on both 
peptides involved in the cross-link, confirming that the cross-link is indeed in-tact, at 
least partially, in the recombinant hLOXL2 sample. 
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Figure 5. MS/MS data at m/z 1299 corresponding to the lysyl-tyrosol crosslink common in all LOX and 
LOXL proteins. (A) Illustrates the chemical structure of the cross-link. Circled in brown corresponds to a 
phenyl hydrazine group that was attached to the protein before protease digestion to ensure the cross-





3.4 Concluding remarks 
A recombinant form of hLOXL2 expressed in insect cells was successfully 
analyzed by mass spectrometry, with near complete characterization of the protein 
sequence.  Protein sequence coverage was greater than 90% with all non-detected 
peptides having a sequence of 5 amino acids or less.  In addition, 9 different 
glycopeptides were identified, with glycoforms present at both N-linked glycosylation 
sites.  The glycosylation that was detected was consistent with the glycoforms known to 
be present in Drosophila cells.  Lastly, the in-tact lysyl tyrosol cross-link was detected in 
the LTQ Velos MS data, completing the analysis of hLOXL2 including its post-
translational modifications. 
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CHAPTER 4 




Glycoproteomics, the study of the glycome attached to proteins, is a vital 
research field because as many as 50% of proteins in the human body are 
glycosylated.1  Glycoproteins are not only common, but the glycans on the proteins are 
significant because they are known to play important biological roles in the body, 
including cell-cell interaction, cell recognition, and protein regulation.2  While proteins 
are genetically encoded, the glycosylation on proteins depends on the glycosylating 
enzymes that are present and the local cell environment.  Therefore, the amount of 
enzymes and cofactors involved in glycosylation affect the extent of glycosylation on the 
glycoprotein.3  Changes in glycosylation are known to occur with the onset of certain 
diseases such as cancer.4-6  Thus, detection methods to monitor changes in 
glycosylation of glycoproteins are essential to determine possible biomarkers for cancer 
and other diseases. 
Methods to monitor changes in glycosylation of proteins are not just important for 
biomarker studies.  These methods are also important for pharmaceutical development, 
since glycoproteins have become increasingly desirable targets as therapeutic agents. 
Some example glycoprotein-based pharmaceuticals include erythropoietin,7 follicle 
stimulating hormone,8 thyroid stimulating hormone,9 and vaccine candidates, such as 
the heavily glycosylated envelope glycoprotein on the surface of the HIV virus.10-12  
Profiling and quantifying the glycosylation on these products is important because 
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studies indicate that glycosylation in cell expression systems can differ from the 
glycosylation that occurs in the human body,10 and researchers are currently striving to 
overcome this problem by modifying the glycosylation, or humanizing it, during protein 
production.13, 14  Therefore, as methods are developed for humanizing glycosylation, a 
quantitative method that distinguishes between glycosylation profiles on native and 
modified glycoproteins is imperative.  
There are two options for quantifying glycosylation on proteins, quantifying the 
glycans after enzymatic or chemical cleavage from the protein, or quantifying 
glycopeptides.  While glycan analysis is clearly a more established technique,15-18 this 
approach restricts the amount of information one can obtain about the glycosylation 
profile.  For example, in purified, multiply glycosylated proteins, the study of released 
glycans would only provide aggregate information about the glycosylation on a protein, 
and it would not provide information about the glycosylation profile at a specific 
glycosylation site.  Yet, it is well established that monitoring glycosylation profiles at 
individual glycosylation sites is important because the glycosylation at particular sites in 
a protein can modulate the protein’s structure, function, or metabolic clearance.19  Since 
many therapeutic proteins are multiply glycosylated, including all the examples 
mentioned above, the analysis of released glycans is problematic in that it does not 
provide glycosylation site-specific information about the glycosylation profiles of the 
protein.   
In biomarker analysis quantifying the released glycans has an additional 
disadvantage in that all the information about the proteins from which the glycans 
originated is lost.  This introduces many problems in biomarker discovery, such as not 
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being able to identify whether or not the glycan’s concentration increased because a 
protein containing that glycan was overexpressed or if one or several proteins’ 
glycosylation profile changed, causing the glycan to be more abundant, even though the 
protein level(s) are not altered.4  In contrast to glycan analysis, glycopeptide analysis 
provides glycosylation site-specific information for purified proteins17, 20, 21 and it could 
potentially be useful in distinguishing between glycosylation changes and protein 
expression changes, since the protein information is encoded in the glycopeptide.  For 
the reasons described herein, we are pursuing quantitative methods for glycopeptides. 
There are two strategies to quantify changes in the glycosylation of proteins, 
either differentially labeling sets of samples or using label-free approaches.  Several 
labeling techniques exist, including those with detection by optical methods22, 23 and 
mass spectrometry.24-26  One common quantitation strategy using labeling and optical 
detection involves the use of lectins to bind glycoproteins in complex samples, and 
detection of different types of glycosylation due to differential binding of the lectins.  
Because different lectins have different specificities for classes of N-linked glycans, it is 
possible to use lectins to distinguish between high mannose and complex type 
glycosylation, for example.  Detecting the binding of lectins to glycans, glycopeptides, or 
glycoproteins is done by either tagging the lectins22, 27 or tagging the analyte23 with a 
fluorophore, followed by the monitoring of a change in fluorescence upon binding.   If 
the ultimate quantitative goal is to detect changes in classes of N-linked glycans, optical 
methods that detect differences in lectin binding are ideal and have very low detection 
limits.  However, the use of lectin microarrays is incapable of observing subtle 
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glycosylation changes, such as a change in the number of mannoses present on a high 
mannose glycan.23 
If detecting subtle changes in glycosylation is required, such as distinguishing 
between the addition or subtraction of one monosaccharide unit between glycoprotein 
samples, other detection strategies, for example mass spectrometry, must be 
employed.  Quantitative MS analysis of glycosylated species using isotopic labels is a 
growing field.  Currently, methods are available to analyze glycans directly,25, 26, 28-31 and 
the strategy used in some of these approaches could potentially be applied to 
glycopeptide analysis.  The biggest draw-back is that many of these labeling methods 
are also limited to two sample sets, a control group and a test group; therefore, if more 
samples need to be compared to one another, such as analyzing the glycosylation 
differences between five different vaccine candidates, binary labeling approaches 
become difficult to implement. 
An alternative strategy for accomplishing a quantitative analysis is to use label-
free approaches.  These methods have the potential to compare multiple samples with 
ease.  Changes in intensities of mass spectral peaks have been assessed by 
comparing different sample sets through either glycan analysis4 or glycopeptide 
analysis.32  Because signal intensities can vary between mass spectrometric samples, 
label-free approaches are not as commonly used for quantitative analysis.26, 33  
To alleviate much of the variation due to changes in MS response among 
samples, normalization of data has been applied in proteomics studies.34-36  Old, et. al. 
employed a normalization technique that is easily adaptable to direct injection mass 
spectrometry by dividing intensities of individual peaks by the total intensity from all 
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peaks in the spectrum.33   In the work presented here, this concept of normalization is 
built-upon to produce a label-free quantitative method for glycopeptide analysis.  While 
in the proteomic field, one can obtain reliably quantitative data by normalizing the data 
to the total ion abundance,33 this method is potentially problematic for glycopeptide 
analysis, because the glycopeptides ionize weakly, compared to the non-glycosylated 
peptides that may also be present.  Therefore, small changes in the presence of a non-
glycosylated interferent could impart large variability in a quantitative assay, when the 
total ion current is used to normalize the ion abundances of the analytes.  To remedy 
this problem, a new normalization method is described herein, where the ion abundance 
from each glycopeptide is divided by the total intensity of all glycopeptide peaks present 
in a given spectrum (excluding all ions that are not assigned as glycopeptides).  As 
demonstrated herein, this normalization produces reproducibly quantitative, label-free 
data.  
The second major innovation of this work is using a two-tiered quantitative 
analysis.  In the first tier of the analysis, the abundances of glycopeptide ions within a 
given sample are compared to each other.  This internal analysis is used to generate a 
glycosylation profile for the sample, where the abundance of each glycoform is rank-
ordered (from smallest to largest) within the sample.  The second tier of the analysis 
involves comparing this generated glycopeptide profile from one sample to the profile of 
another sample.  By comparing whole profiles, and not just the abundance of a given 
glycoform, one can readily discriminate between changes in the overall glycosylation 
profile of a protein and changes in the abundance of a given glycoprotein, present in a 
mixture of other species.  The described method, which presents a new normalization 
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method custom-designed for the challenges of glycopeptide analysis, and a new 
approach to glycosylation profiling, where internal and external analyses are completed 
in parallel, is useful for those interested in glycosylation profiling of biopharmaceuticals 
as well as those quantifying mixtures of glycoproteins for various applications, including 
biomarker analysis.  
4.2 Experimental 
4.2.1 Materials and Reagents 
All reagents were obtained in high purity from Sigma Aldrich except when noted 
otherwise.  Ribonuclease B (RNase B) >80% pure, asialofetuin, urea, α-mannosidase 
from Canavalia ensiformis, dithiothreitol (DTT), iodoacetamide (IAA), acetic acid, 
Sepharose® CL-4B, HPLC grade 1-butanol, and HPLC grade ethanol were all 
purchased from Sigma Aldrich (St. Louis).  Sequencing grade modified trypsin was 
purchased from Promega (Madison, WI).  Ammonium bicarbonate (NH4HCO3) was 
purchased from Fluka (Milwaukee, WI).  HPLC grade methanol was purchased from 
ThermoFisher Scientific (Fairlawn, NJ).  Water was purified by a Millipore Direct Q-3 
water purification system (Billerica, MA). 
4.2.2 Enzymatic Glycan Trimming with α-mannosidase 
 To analyze glycosylation change, one RNase B sample was subjected to 
cleavage by the enzyme α-mannosidase as described by Toumi et al.37  Briefly, 
approximately 300 µg of RNase B was dissolved in enough 10 mM NH4HCO3 (pH 5.0) 
to make 2 mg/mL. α-mannosidase was added in an enzyme:protein ratio of 1:1000 
(mol/mol).  The sample was allowed to incubate for 24 hours in a 37 °C oven.  Enough 
NaOH was added to raise the pH of the sample to approximately pH 8.0.  The sample 
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was then treated as described below for protease digestion, glycopeptide enrichment, 
mass spectrometry, and data analysis. 
4.2.3 Glycoprotein Protease Digestion 
Approximately 300 µg of glycoprotein was dissolved in 25 mM NH4HCO3 (pH 7.5 
– 8.0) containing 4 M urea, to a glycoprotein concentration of 1 mg/mL (asialofetuin) or 
2 mg/mL (RNase B).  To this solution, dithiothreitol (DTT) was added to a final 
concentration of 15 mM, and it was incubated at room temperature for 1 hr.  Following 
the incubation, iodoacetamide (IAA) was added to a final concentration of 25 mM, and 
the reaction was stored at room temperature, in the dark, for 1 hr.  Additional DTT was 
added to a final concentration of 40 mM to neutralize excess IAA.  The solution was 
diluted with 25 mM NH4HCO3 until the urea concentration was less than 1 M.  Trypsin 
was added at a 1:50 (w/w) protease/glycoprotein ratio.  The solution was allowed to 
incubate at 37 °C for 18 hr and stopped by the addition of 1 µL acetic acid per 100 µL 
solution. 
4.2.4 Glycopeptide Enrichment 
To remove the nonglycosylated peptides from samples, a method adapted from 
Wada et al.38-40 was used.  Briefly, the digest solution was added to 800 µL of 5:1:1 (v/v) 
1-butanol/ethanol/water and 25 µL Sepharose® CL-4B, and shaken gently for 45 
minutes before centrifugation and extraction of the solution layer.  Samples were 
washed twice with the addition of 1 mL 5:1:1 (v/v) 1-butanol/ethanol/water with gentle 
shaking for 5 minutes followed by the same centrifugation and extraction.  After 
washing, 1 mL of 1:1 (v/v) ethanol/water was added, and samples were allowed to 
stand for 30 minutes, followed by gentle shaking for 30 minutes.  The samples were 
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centrifuged, and the solution layer was extracted and collected.  The ethanol/water 
extraction step was repeated a second time.  The combined samples were dried using a 
Labconco centrivap cold trap (Kansas City, MO) and stored at -20 °C until use. 
For the quality control studies, the samples were reconstituted prior to MS 
analysis in 1:1 (v/v) water/methanol containing 0.5% acetic acid, to a final glycopeptide 
concentration of 10 µM.  After the initial MS analysis, the remaining RNase B was 
stored in the reconstituted solvent at -20 °C for 8 weeks for a second MS analysis 
testing the method’s robustness. 
For the mixture analysis experiments, RNase B and asialofetuin glycopeptide 
digest samples were each reconstituted in 100 µL 1:1 (v/v) water/methanol containing 
0.5% acetic acid.  The reconstituted samples of asialofetuin and RNase B glycopeptides 
were combined into four separate vials in varying concentrations.  A total of 4 samples 
were prepared where the asialofetuin glycopeptides retained a fixed concentration of 1 
µM, and the RNase B glycopeptide concentration prepared at 1 µM, 3 µM, 5 µM, and 10 
µM, respectively, in each mixture vial (See Table 1).   
 
Table 1. Glycoprotein Mixture Concentrations 
Sample # 1 2 3 4 
RNase B 1 µM 3 µM 5 µM 10 µM 
Asialofetuin 1 µM 1 µM 1 µM 1 µM 
 
4.2.5 Mass Spectrometry 
MS and MS/MS data were acquired on a  Thermo electrospray ionization - linear 
ion trap - Fourier transform ion cyclotron resonance - mass spectrometer, ESI-LTQ-
FTICR-MS (San Jose, CA), containing a 7 Tesla actively shielded magnet.  The 
samples were injected by direct infusion at a flow rate of 1 µL/min in positive ion mode.  
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The spray voltage was optimized to maximize ion signal, and the value ranged between 
2.8 and 4.0 kV.  The nebulizing gas, N2, was set to 10 psi, and the capillary temperature 
was 200 °C.  MS data were acquired with 100,000 resolution for m/z 400, over a mass 
range of m/z 500 – 2000 for RNase B and a mass range of m/z 800 – 2000 for 
asialofetuin.  For all MS1 data, 50 scans (with each containing 10 microscans) were 
averaged.  For MS/MS data, the precursor ion was isolated with a 2 Da isolation range; 
the activation time was set to 30 ms, the activation qz was 0.250, and the activation 
energy was 30%, as defined by the instrument software.  There were 20 to 30 scans 
(each containing 10 microscans) averaged during acquisition of MS/MS data.  The 
instrument software used was Xcalibur version 1.4 SR1 (ThermoFisher Scientific San 
Jose, CA). 
4.2.6 Data Analysis 
The glycopeptide ions were assigned by matching theoretical masses to the 
actual masses acquired in the MS data.  Prediction tables of possible theoretical 
glycopeptide masses were constructed for each glycoprotein studied.  The prediction 
table was generated by the following steps:  The amino acid sequence of each protein 
was obtained from Uniprot (http://beta.uniprot.org), and a theoretical tryptic digest of the 
given glycoprotein was completed by importing that sequence into Protein Prospector 
(http://prospector.ucsf.edu/), which calculates the possible tryptic fragments.  The mass 
of the resulting tryptic fragments were adjusted to account for the alkylation of cysteine 
residues by iodoacetamide.  The peptide masses that contained glycosylation sites 
were added to possible N-linked glycan masses to give predicted glycopeptide masses.  
The glycan masses used in this case were the known glycans that are appended to 
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these proteins, as described in references 41 and 42, for asialofetuin and RNase B, 
respectively.  After combining the peptide masses with the known glycan masses, the 
calculated glycopeptide masses were converted to m/z’s (for the +1, +2, +3, +4, and +5 
charge states) for comparison to the MS1 data.  A maximum of two missed tryptic 
cleavages was considered, as well as the presence of protonated and sodiated 
glycopeptide peaks.  Possible peak identities from the MS data were confirmed through 
analysis of MS/MS data taken on each peak in the spectrum, as described previously.43 
4.2.7 Data Treatment for Quantitative Method 
 After identifying all the glycopeptide peaks in the spectrum, six steps were taken 
to process the data for quantitative analysis.  The steps were:  1) Peak lists of m/z and 
intensity were generated in Xcalibur, and transferred to Microsoft Excel.  2) The first four 
isotopic peaks of each glycopeptide ion were summed to obtain each glycopeptide’s 
peak intensity.  3) Glycopeptide peak intensities from all glycopeptide peaks in a 
spectrum were summed to calculate the total glycopeptide intensity.  4) The 
glycopeptide peak percentage was computed by Equation 4.1, below.  This percentage 









5) Glycopeptide peak percentages corresponding to the same glycopeptide 
composition, but containing different charge states and/or charge carriers, were 
summed to give the glycopeptide percentage.  If glycopeptides from a given 
glycosylation site also were generated with differing levels of missed tryptic cleavages, 
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these species were also combined into one glycopeptide percentage.  This percentage 
is a measure of how abundant a given glycopeptide composition is in the sample, 
regardless of whether or not it ionizes as a single peak, or as several peaks 
corresponding to different charge states, different numbers of sodiated adducts, or 
different lengths of peptide, due to missed tryptic cleavage.  6) Glycopeptide 
percentages were rank ordered to determine which glycopeptides were most abundant 
in the spectrum, and the rank order between different samples was compared. 
4.3 Results and discussion 
4.3.1 Developing a quantitative method for glycopeptides 
 
 Since the goal is to develop a label-free quantitative approach for glycopeptides, 
the first problem that must be overcome is the fact that ion abundances in mass spectra 
are not very reproducible in run-to-run analyses.  Figure 1 demonstrates this by showing 
MS data of glycopeptides generated from two replicate samples of glycopeptides 
generated from digesting asialofetuin with trypsin.  The brown and red stars in Figure 1 
label peaks that correspond to two different charge states of a single glycopeptide 
composition, the 4+ and 5+ charge states, respectively.  The intensity of the peaks 
labeled with the brown stars do not change between Figure 1a and b, because this is 
the base peak in both spectra.  The peaks labeled with red stars, on the other hand, 
have a much higher intensity in Figure 1a compared to Figure 1b, demonstrating that 
the ions partitioned differently into different charge states in the two analyses.  The 
insets in Figure 1a and b show the intensities of sodiated adducts are also different, 
when the two spectra are compared.  The peaks labeled with green stars, which 
 117 
correspond to sodiated adducts of some of the glycopeptides, have much lower 
intensities in Figure 1b compared to Figure 1a.  
 
Figure 1. (a) and (b) Mass spectra from two different glycopeptide samples of asialofetuin. Red and 
brown stars show the same glycopeptide in different charge states; the intensities of each of the charge 
states vary from sample to sample.  Insets:  a zoomed-in region of the spectrum containing multiple 
sodiated adducts of the glycopeptides.  The green stars indicate sodiated adducts of glycopeptides 
whose intensity changes in spectrum a and b. 
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Consequently, the distribution between charge states and sodiated adducts of the 
glycopeptide peaks in Figure 1a is different than the distribution of the glycopeptide 
peaks in Figure 1b.  Therefore, it makes sense that the peaks from Figure 1a and b 
would have poor reproducibility when compared by their relative abundance alone.  
To alleviate the problem that changes in the form in which the peaks ionize leads 
to irreproducible peak intensity data, the relative abundances of the peaks containing 
the same glycopeptide composition but differing in the charge state and charge carrier 
were combined.  By combining these values, the problem that the peaks partition 
differently into different charge states is mitigated.  Once all the charge states and 
charge carriers for a particular glycopeptide composition are combined, we report the 
results as a percent of the total glycopeptide ion signal, and this value is henceforth 
referred to as the glycopeptide percentage.  [Reporting the values as percentages of all 
the glycopeptides present in the spectrum is a normalization method used to mitigate 
the run-to-run ionization discrepancies that are known to be problematic in label-free 
quantitative approaches, as described in the introduction.]  After obtaining the 
glycopeptide percentages for each of the different glycopeptide compositions, the 
compositions are ordered based on their percentage from smallest to largest (rank 
ordered), so an internal comparison of the glycan profile can be made.  A list of all the 
identified glycopeptide ions from asialofetuin are shown in Table 2, and the chart is 
color-coded to show which species’ ion abundances were combined.  For example, all 
the blue entries correspond to glycopeptides with the peptide sequence 
RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR.  The darker blue indicates the 
biantennary glycans containing that amino acid sequence, and the lighter blue indicates 
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the triantennary glycans.  The intensities of peaks with the same color are combined to 
produce a single glycopeptide percentage. 
 










Na Peptide Carbohydrate 
1059.6757 1059.6767 0.9 5+ 0 RPTGEVYDIEIDTLETTCHVLDP
TPLANCSVR 
[Hex]5[HexNAc]4 
1064.0722 1064.0783 5.7 5+ 1 “ “ 
1068.4687 1068.4746 5.5 5+ 2 “ “ 
1121.8122 1121.8183 5.4 3+ 0 LCPDCPLLAPLNDSR “ 
1129.1397 1129.1438 3.6 3+ 1 “ “ 
1132.7022 1132.7059 3.3 5+ 0 RPTGEVYDIEIDTLETTCHVLDP
TPLANCSVR 
[Hex]6[HexNAc]5 
1137.0987 1137.1055 6.0 5+ 1 “ “ 
1141.4952 1141.5009 5.0 5+ 2 “ “ 
1145.8917 1145.8944 2.4 5+ 3 “ “ 
1150.2882 1150.2762 10.4 5+ 4 “ “ 
1160.5443 1160.5529 7.4 4+ 0 VVHAVEVALATFNAESNGSYLQ
LVEISR 
[Hex]5[HexNAc]4 
1164.5106 1164.5156 4.3 3+ 0 KLCPDCPLLAPLNDSR “ 
1166.0400 1166.0479 6.8 4+ 1 VVHAVEVALATFNAESNGSYLQ
LVEISR 
“ 
1171.5356 1171.5389 2.8 4+ 2 “ “ 
1171.8381 1171.8426 3.8 3+ 1 KLCPDCPLLAPLNDSR “ 
1243.5230 1243.5300 5.6 3+ 0 LCPDCPLLAPLNDSR [Hex]6[HexNAc]5 
1250.8505 1250.8559 4.3 3+ 1 “ “ 
1251.8274 1251.8252 1.8 4+ 0 VVHAVEVALATFNAESNGSYLQ
LVEISR 
“ 
1257.3230 1257.3286 4.5 4+ 1 “ “ 
1258.1780 1258.1814 2.7 3+ 2 LCPDCPLLAPLNDSR “ 
1262.8186 1262.8220 2.7 4+ 2 VVHAVEVALATFNAESNGSYLQ
LVEISR 
“ 
1265.5055 1265.5081 2.1 3+ 3 LCPDCPLLAPLNDSR “ 
1268.3143 1268.3221 6.1 4+ 3 VVHAVEVALATFNAESNGSYLQ
LVEISR 
“ 
1273.8099 1273.8070 2.3 4+ 4 “ “ 
1286.2213 1286.2286 5.7 3+ 0 KLCPDCPLLAPLNDSR “ 
1293.5488 1293.5582 7.3 3+ 1 “ “ 
1300.8763 1300.8730 2.5 3+ 2 “ “ 
1308.2038 1308.2108 5.4 3+ 3 “ “ 
1324.3428 1324.3526 7.4 4+ 0 RPTGEVYDIEIDTLETTCHVLDP
TPLANCSVR 
[Hex]5[HexNAc]4 
1329.8385 1329.8471 6.5 4+ 1 “ “ 
1335.3341 1335.3426 6.4 4+ 2 “ “ 
1415.6259 1415.6355 6.8 4+ 0 “ [Hex]6[HexNAc]5 
1421.1215 1421.1297 5.8 4+ 1 “ “ 
1426.6171 1426.6263 6.4 4+ 2 “ “ 
1432.1128 1432.1185 4.0 4+ 3 “ “ 
1437.6084 1437.6084 0.0 4+ 4 “ “ 
1547.0587 1547.0695 7.0 3+ 0 VVHAVEVALATFNAESNGSYLQ
LVEISR 
[Hex]5[HexNAc]4 
1554.3842 1554.3688 9.9 3+ 1 “ “ 
1668.7674 1668.7771 5.8 3+ 0 “ [Hex]6[HexNAc]5 
1676.0949 1676.1073 7.4 3+ 1 “ “ 
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1682.2147 1682.2204 3.4 2+ 0 LCPDCPLLAPLNDSR [Hex]5[HexNAc]4 
1683.4224 1683.4358 8.0 3+ 2 VVHAVEVALATFNAESNGSYLQ
LVEISR 
[Hex]6[HexNAc]5 
1765.4547 1765.4575 1.6 3+ 0 RPTGEVYDIEIDTLETTCHVLDP
TPLANCSVR 
[Hex]5[HexNAc]4 
1864.7808 1864.7876 3.6 2+ 0 LCPDCPLLAPLNDSR [Hex]6[HexNAc]5 
1Mass error is reported in ppm. 
The color of the rows (blue, red, or green) represent the three glycosylation sites of asialofetuin, whereas 
the darker and lighter shades of a given color correspond to biantennary and triantennary glycans, 
respectively. Ion abundances corresponding to the same color and shade are added together to generate 
the “glycopeptide percentage” for each species.  
 
Figure 2 illustrates the benefit of combining the different charge states and 
charge carriers for the asialofetuin glycopeptide data.  Figure 2a shows a portion of the 
rank order of ion abundances between the two asialofetuin samples from Figure 1 when 
the ion abundances are not combined, prior to ranking the glycopeptides from smallest 
to largest.  The rank order is clearly very different between the two samples.  However, 
once the different charge states and charge carriers for each of the glycopeptide 
compositions are combined, the rank order is highly reproducible between the two 
samples (Figure 2b). 
 121 
 
Figure 2. (a) Rank order of glycopeptide ions from the data in Figure one.  (b) Rank order of glycopeptide 
compositions, after combining all charge states and sodium adducts of ions with the same composition, 
prior to rank-ordering the components.  Reproducible glycosylation profiles are achieved only in 2(b), 
when charge states and sodium adducts of the same species are combined. 
 
4.3.2 Quality Control Experiment 1 – Robustness 
 Since the goal was to develop a robust quantitation method that can detect 
changes in glycopeptides’ intensities for different samples, one important feature is that 
the method must produce the same results for the same glycoprotein batch.  For 
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example, small differences that could be introduced during digestion or glycopeptide 
enrichment and dilution for MS analysis, should not cause changes in the quantitation 
results.  Otherwise, the method would not be robust.  To test robustness, a quality 
control experiment was developed where four replicate samples of asialofetuin were 
each digested and prepared separately.  After each sample was subjected to MS 
analysis, the glycopeptide percentages were calculated as described above, and were 
subsequently rank ordered, by percentage, from smallest to largest.  The results of this 
experiment are displayed in Figure 3a.  It is evident from the figure that the same rank 
order was observed for all four samples. However, the percentages between each 
sample tended to vary slightly, albeit not enough to change the rank order.  This 
variability in percentage of asialofetuin glycopeptides is attributed to change in the 
distribution of sodiated adducts between samples.  Different numbers of sodiated 
adducts can have slightly different ionization efficiencies.  Therefore, when samples 
produce spectra with different intensities of sodiated adducts, combining the 
percentages of the different sodiated adducts can introduce a small variability in the 
percentages of each glycopeptide composition.  This is not a significant problem, 
however, because the changes are small enough that the rank order did not vary 
between the samples. 
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Figure 3. Similarity of the glycopeptide profiles for asialofetuin (a) and RNase B (b). The percentage of 
each glycopeptide composition is plotted for four replicate samples. The glycopeptide compositions are 
shown on the x-axis in order of their abundance in the spectrum. In each case, the rank order (smallest 
percentage to largest percentage) does not change; small fluctuations are observed in the actual 
percentage of each glycopeptide composition among the four replicate samples. 
 
4.3.3 Quality Control Experiment 2 – Applicability to Different Glycoproteins 
 Once the method was confirmed to produce reproducible results for asialofetuin, 
a second glycoprotein with very different properties than asialofetuin was analyzed to 
ensure the method is applicable for a wide variety of glycoproteins.  RNase B was 
chosen for the analysis because it is much smaller than asialofetuin; it has only one 
glycosylation site; and it has a different type of glycosylation, high mannose type 
glycans.  See Table 3.  RNase B was subjected to the same sample preparation 
conditions as asialofetuin.  Four replicate samples of RNase B were digested and 
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analyzed.  Unlike the asialofetuin data, RNase B glycopeptides did not ionize as 
sodiated adducts.  The RNase B glycopeptides did ionize in multiple charge states, and 
the spectra also contained peaks corresponding to missed tryptic cleavages of the 
glycopeptides (data not shown).  The missed cleavages are likely the result of the 
glycosylation blocking the cleavage site, as described earlier,44 since several arginine 
and lysine residues are located very near the glycosylation site.  See the amino acid 
sequence in Table 3.  These missed tryptic cleavages could potentially interfere with  
 
Table 3. Comparison of Glycoproteins 




















1 N-linked glycosylation site 
 
3 N-linked glycosylation sites 
 





reproducible quantitative analysis, if the digestions do not generate identical proportions 
of peptides with missed tryptic cleavages near the glycosylation sites.  To mitigate the 
potential for quantitative error due to differences in the digestion, glycopeptide peaks 
corresponding to a given glycosylation site and a given glycan composition were 
combined with species that contained the same glycan composition and glycosylation 
site, but different levels of missed tryptic cleavages.  The results from the RNase B 
experiments are illustrated in Figure 3b.  The RNase B glycopeptide data also exhibits a 
consistent rank order among the replicate samples. 
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4.3.4 Quality Control Experiment 3 – Instrument precision 
 The use of a mass spectrometer over extended time frames can lead to 
reproducibility problems in label-free quantitative assays.  Therefore, to ensure that 
minor changes in the instrument conditions do not lead to inaccuracies in assigning the 
rank order of glycopeptides, the four samples of glycopeptides from RNase B were run 
on two different dates, eight weeks apart.  Between analyses, the samples were stored 
at -20 °C.  Under these conditions, the RNase B glycopeptides do not degrade; 
therefore any changes in the rank order of the glycopeptide compositions would be 
attributed to instrument variability over time.45  Prior to using our quantitative method on 
the two sets of data, we first determined whether or not the mass spectra showed 
deviations in peak intensities between weeks zero and eight, by comparing the raw ion 
abundances for each of the glycopeptides.  Table 4 shows the results for the relative 
abundances of several peaks that were acquired from one RNase B glycopeptide 
sample, before and after the 8 week storage conditions.  The relative abundance  
increases in the 3+ charge state in week 8 compared to week 0, while the relative 
abundance in the 2+ charge state decreases in week 8, compared to week 0.  This is 
another example that shows the ions can partition themselves differently into different 
charge states.  In this case, drastically different ion abundances were acquired for the 
exact same sample.  Fortunately, the quantitative method described herein is designed 
to accommodate this variability by combining glycopeptide peak percentages for the 







Table 4. Differences in relative abundance for glycopeptide ions from RNase B:   
Charge 







735.9958 32.7 77.6 
3+ [Hex]6[HexNAc]2 
+ SRNLTKDR 
790.0134 34.2 66.8 
3+ [Hex]7[HexNAc]2 
+ SRNLTKDR 
844.0310 14.8 31.1 
3+ [Hex]8[HexNAc]2 
+ SRNLTKDR 
898.0486 36.1 50.8 
3+ [Hex]9[HexNAc]2 
+ SRNLTKDR 


























aTwo data sets using the same sample, analyzed eight weeks apart.  
 
glycopeptide peak percentages as described above, the rank order of RNase B 
glycopeptides was obtained, and the data is shown in Figure 4 for the two different time 
points. The glycopeptide percentages for RNase B glycopeptides illustrated in Figure 4 
show high reproducibility, small standard deviations, and the rank order is retained 
between the two runs. 
The above experiments demonstrate that for a purified sample, the quantitative 
method described produces reproducible data, even under different instrumental 
conditions, and the reproducibility is unaltered after repeating the protease digestion 
and sample preparation conditions.  Also, the method successfully analyzed two 
different glycoproteins that had a variety of different features, including varying numbers 
of glycosylation sites and different types of glycosylation.  In summary, these studies 
demonstrate that the quantitative method described would be useful for classifying 
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glycosylation changes in purified proteins, which is useful in a variety of 




Figure 4. Graphical depiction of the quantified amounts of RNase B glycopeptides at two different time 
points. The mean from four digest samples was plotted. Error bars indicate the standard deviation. The 
glycopeptides are plotted from left to right in order of increasing abundance. The rank order does not 
change, even when the sample is re-analyzed eight weeks after the original analysis date. 
 
4.3.5 Mixture Analysis 
In addition to characterizing the glycosylation on biopharmaceuticals, it would be 
ideal if this method of quantifying glycosylation profiles could also be used in other types 
of applications, for example in studies where a mixture of proteins is present.  When a 
mixture of glycopeptides is analyzed, one current roadblock is being able to determine 
why the particular glycopeptide ion has changed in abundance, i.e. is it due to changes 
in glycosylation on a given protein or due to changes in the protein’s net concentration, 
relative to the other species being analyzed?4  Our method, which characterizes the 
entire glycosylation profile for a given glycoprotein as part of the quantitation process, is 
ideally suited to solving this problem.   
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To demonstrate that the quantitative method described herein can also 
distinguish between glycosylation changes and net protein abundance changes when 
proteins are present in a mixture, glycopeptides from the two proteins described above 
were combined in several different ratios, and the resulting samples were analyzed.  In 
each case, glycopeptides from asialofetuin were present at a concentration of 1 µM, 
while the glycopeptides from RNase B were present at varying concentrations, between 
1 and 10 µM.  (See Table 1).  MS data of the mixed samples was acquired, and the 
rank order for each of the glycopeptides present was obtained, as described previously.  
The quantitative results are shown in Figure 5.  This Figure shows data for the RNase B 
glycopeptides for the four samples.  Regardless of the relative concentrations of the two 
proteins, the rank order of the glycans for the given glycoprotein, RNase B, did not 
change.  In every case, the Man9 glycopeptides from RNase B were present in lowest 
abundance and the Man5 glycopeptides were present in highest abundance, among the 
RNase B glycoforms.  This demonstrates that varying the concentration of protein does 
not impact the rank order of the glycopeptides for a given glycoprotein.  In addition, the 
order observed in Figure 5 is the same order as observed for RNase B alone, (in Figure 
3b and 4), demonstrating that the presence of other proteins does not interfere with the 
method’s ability to reproducibility rank order the glycopeptides.  Most importantly, when 
one compares the data for a given glycopeptide, for example, Man5, the data in Figure 
5 clearly demonstrate that the glycopeptide percentages increase as the concentration 
of the protein increases.  Therefore, the data described herein can clearly distinguish 
between changes in a glycosylation profile and changes in a protein’s concentration.  
For the four samples in Figure 5, the glycosylation profile was identical; yet the 
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concentrations of a given glycopeptide increased as the protein concentration 
increased.  If the concentration of the protein remained the same but the glycan profile 
had been altered, the rank order of glycans would vary between the samples, but the 
overall glycopeptide concentration for the sum of all the glycopeptides of a given protein 
would remain approximately the same. 
 
Figure 5. (a) Glycopeptide profiles for RNase B in mixtures of RNase B and asialofetuin.  Glycopeptide 
percentages of all the RNase B glycoforms are increased as the concentration of RNase B is increased in 
the mixture; rank order of the glycoforms is conserved. (b) RNase B before and after cleavage with α-
mannosidase. Man8 and Man9 decreased in glycopeptide percentage, while Man1, Man2, Man3, and 
Man4 increased in glycopeptide percentage. 
 
4.3.6 Monitoring Changes in Glycosylation 
The quantitative method proposed herein has been subjected to many 
experimental conditions described above to ensure that is reproducible, robust, and that 
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changes in glycoprotein concentration can be assessed.  One additional experiment 
was completed to ensure that this method can indeed quantify changes in glycosylation.   
RNase B was subjected to a commercially available enzyme capable of cleaving 
mannose residues, α-mannosidase from Canavalia ensiformis.  For a complete 
digestion with this enzyme, a 72 hour incubation period was needed.37  A partial 
digestion was more appropriate for analyzing changes in glycosylation, therefore the 
enzyme was only allowed to incubate with RNase B for 24 hours.  Two experiments 
were performed simultaneously; one where RNase B was allowed to be digested with α-
mannosidase and a second experiment with RNase B unmodified.  Figure 5b illustrates 
the results from this experiment.  As can be deduced from the figure, the glycopeptide 
percentage from Man8 and Man9 were reduced, and the glycopeptide percentage from 
Man1, Man2, Man3, and Man4 were increased, as expected with an enzyme that 
cleavage glycan residues.  This clearly shows that the quantitative method is capable of 
monitoring changes in glycosylation. 
This quantitative method is similar to other analytical methods, in that there are 
expectations and limitations to this work.  First of all, it is expected that other methods 
will be used to identify all the possible glycopeptides before using the quantitative 
method.12, 17, 20, 40, 43, 46, 47  Obviously, without proper identification of the glycopeptides, 
the glycosylation profiles may be different when comparing multiple samples.  This 
method is only applicable to glycoproteins containing neutral glycans, as mixtures of 
sialylated, other negatively charged glycan species, and neutral glycans typically require 
the use of both positive and negative mode to accurately identify such species.  Using 
both modes would be extremely difficult for accurate glycosylation profiles to be 
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constructed.  If certain glycoprotein samples were known to have varying levels of 
glycosylation site occupancy, the comparison between samples may produce similar 
results as is seen with glycoprotein concentration changes.  Thus, this method cannot 
distinguish changes in site occupancy from glycoprotein concentration changes.  Even 
though this method has some limitations, its utility for quantifying glycosylation profiles 
has many uses in glycoprotein analysis. 
4.4 Concluding Remarks 
This manuscript describes a new label-free quantitative method that can be 
applied to purified proteins as well as glycoprotein mixtures.  In the mixture analysis, the 
method is able to distinguish between glycoprotein concentration changes and changes 
in glycosylation.  The method was validated with several control experiments.  The first 
control experiment analyzed replicate samples of glycopeptides from one glycoprotein, 
asialofetuin.  The results from this experiment illustrate that the rank order of 
glycopeptides is consistent in all replicate samples, with slight variation in glycopeptide 
percentages.  To be confident that the method would be applicable to a large set of 
glycoproteins, a second glycoprotein, RNase B, with very different properties was 
analyzed.  RNase B results are also very consistent among four replicate samples, and 
the rank order of the glycoforms is retained among the replicate samples.  Because the 
replicate samples in the two glycoproteins studied were digested in different vials before 
analysis, the results demonstrated that minor changes in digestion conditions did not 
alter the rank order.  The third quality control experiment measured the ability of the 
method to tolerate small changes in the instrument conditions.  The same RNase B 
glycopeptide samples were run on two different dates, 8 weeks apart, and subsequently 
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analyzed with the quantitative method.  Similar RNase B glycopeptide percentages 
were observed, with no change in rank order; therefore similar samples can confidently 
be analyzed by this method at different times.  This new quantitative method would be 
useful for anyone studying glycosylation profiles of proteins, either as purified proteins 
(as in the case of pharmaceutical development) or as glycoprotein mixtures, such as in 
the search for glycan-based biomarkers.  
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ASSESSING SECONDARY STRUCTURE OF GLYCOPROTEINS IN THE 
PRESENCE AND ABSENCE OF HIGH MANNOSE N-LINKED GLYCANS 
 
5.1 Introduction 
High mannose glycans are known to be the simplest type of N-linked glycans.  
They are considered the least processed because they have undergone the fewest 
modifications during post-translational processing.1-3  Typically, in humans, these types 
of glycans are rare.  Instead, N-linked glycans become extensively processed in the 
Golgi, after protein folding, to form complex-type N-linked glycans.1,3  It is likely that 
when high mannose glycans are exposed on a human protein, the body recognizes 
these as being from a mis-folded or non-self protein.  Most proteins in the human body 
that contain high mannose glycans on their surface will be removed quickly by mannose 
binding lectins.4, 5  Rapid protein removal is to be avoided when administering 
glycoproteins as therapeutics; otherwise, dosing must be increased.6  Thus, 
pharmaceutical companies interested in developing glycoprotein therapeutics must 
attempt to find an optimal glycan profile for producing their glycoproteins. 
One option for producing proteins with an optimal glycan profile is to consider 
expressing the protein in mammalian cell lines, which typically generate proteins with 
more human-like glycosylation (complex glycans).7  The disadvantage of this route is 
that much lower protein production yields are typical, compared to other cell lines, such 
as yeast or insect cells.8-10  These production platforms produce the protein in much 
higher yields, but they contain non-human, high mannose type N-linked glycans.6   
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Even mammalian cell expression systems can cause problems for the safety and 
efficacy of glycoproteins.  Erythropoietin, for example, is a common glycoprotein drug 
that is expressed in Chinese hamster ovary (CHO) cells.7, 11, 12  The resulting 
glycosylation in erythropoietin is very similar to human glycans; however, there are two 
different types of sialic acids produced in CHO cells, whereas humans only produce one 
of the two sialic acid types, N-acetylneuraminic acid.11, 12  This small change in the type 
of sialic acid residue can cause those who use this drug to experience adverse side 
effects and cause increased rates of clearance from the body.13, 14   
One possible solution is to assess if the glycosylation is even necessary on 
glycoproteins, once the protein is expressed.  In fact, several proteins that are 
glycosylated naturally in the human body, including interleukin-2, tumor necrosis factor-
α, and some interferons have been successfully expressed in Escherichia coli and have 
been shown to be therapeutically active.7  Two major roles of N-linked glycans are to 
aid in protein folding3 and protein secretion from the cells.15  In certain circumstances, 
the glycosylation may have no functional impact on the protein, after expression and 
secretion.  If the glycans are not needed once a protein is folded and secreted, cell lines 
such as yeast and insect cells can be utilized for protein production; and, once 
produced, an enzyme such as Peptide-N-glycosidase F (PNGase F) may be used to 
cleave the glycans from the protein.   
A first step in assessing the need for N-linked glycosylation present on a 
glycoprotein is expression of the protein in either yeast or insect cell line where greater 
protein yield can be obtained, followed by the use of circular dichroism (CD) 
spectroscopy to check for changes in structure and thermal stability due to 
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deglycosylation.16  Recombinant glycoproteins that exhibit measurable changes in 
structure and/or thermal stability by CD spectrscopy after deglycosylation is a key clue 
in confirming that the glycosylation is critical for protein structure and stability.  
Therefore, these types of glycoproteins would need to be expressed in a mammalian 
cell line where human-like glycosylation will be present.  On the other hand, if no 
measurable changes in the structure and thermal stability of a deglycosylated 
glycoprotein are detected, then further steps can be taken to ensure protein activity is 
not impacted after deglycosylation.  This CD spectroscopic pre-screening technique is 
an easy approach requiring relatively small sample amounts for narrowing down 
appropriate cell lines for further development of recombinant therapeutic glycoproteins. 
The work described herein utilizes CD spectroscopy to assess changes in protein 
structure and/or stability due to removal of glycans with PNGase F in glycoproteins.  To 
further confirm that all the glycans were removed from the proteins after PNGase F 
treatment, a protease digestion was performed, followed by LC-MS and MS/MS 
analysis of the resulting peptides and glycopeptides.  A model glycoprotein, 
ribonuclease B (RNase B) was first assessed by this method.  Later, human lysyl 
oxidase-like 2 (hLOXL2) glycoprotein expressed in Drosophila Schneider 2 (S2) cells 
was analyzed.  hLOXL2 is known to be an important protein in development of certain 
cancers,17-19 as well as a potential pharmaceutical drug for those with a deficiency of 
this protein.20  Additionally, both of these glycoproteins contained only high mannose 





5.2.1 Materials and Methods 
Ribonuclease B (RNase B), Trizma® HCl, Trizma® base, NaCl, 
ethylenediaminetetraacetic acid (EDTA), tris(2-carboxyethyl)phosphine (TCEP), 
iodoacetamide (IAA), acetic acid, and formic acid were purchased from Sigma (St. 
Louis, MO).  Peptide-N-glycosidase F (PNGase F) from Flavobacterium 
meningosepticum was purchased from New England BioLabs (Ipswich, MA).  
Acetonitrile (CH3CN) was purchased from Fisher (Fair Lawn, NJ).  Sequencing grade-
modified trypsin was purchased from Promega (Madison, WI).  Water was purified in 
house with a Millipore Direct-Q® UV 3 water purification system (Billerica, MA) that had 
a resistance > 18 MΩ.  Human lysyl oxidase (hLOXL2) expressed in Drosophila 
Schneider 2 (S2) cells was obtained from the Mure lab at the University of Kansas 
(Lawrence, KS).  See Chapter 3 for more details about the hLOXL2 glycoprotein. 
5.2.2 Preparation of Glycoprotein Stock Solutions 
RNase B was diluted to 2 mg/mL in 20 mM Tris buffer, pH 7.8 and 50 mM NaCl.  
hLOXL2 was supplied at 2 mg/mL in 100 mM Tris, pH 8.5, 150 mM NaCl, and 1 mM 
EDTA.  Next, 75 µL aliquots of the 2 mg/mL stocks solutions were flash frozen in liquid 
nitrogen.  The vials were then stored at -80 °C until ready for CD analysis. 
5.2.3 Circular Dichroism (CD) Spectroscopy 
Approximately 2 days prior to performing CD spectroscopy, vials containing the 2 
mg/mL protein samples were slowly thawed by storing them at -20 °C for ~8 hrs, then 
storing at 4 °C overnight.  Glycoprotein samples requiring deglycosylation were treated 
with 1 µL of 1:30 diluted PNGase F (a deglycosylating enzyme) for each N-linked 
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glycosylation site present in the proteins (1 µL of PNGase F for RNase B and 2 µL of 
PNGase F for hLOXL2).  Samples containing PNGase F were incubated at 37 °C for 24 
hrs, for glycan removal.  Samples not being deglycosylated were also incubated at 37 
°C oven for 24 hrs, to ensure any protein degradation caused by the incubation would 
be the same in all samples.  Immediately prior to CD analysis, samples were diluted in 
the original buffer to 0.5 mg/mL.  
For the CD experiments, the “blank” sample consisted of the buffer from a given 
glycoprotein solution.  The same amount of PNGase F added to glycoprotein was also 
added to the blank.  The blank was run at the beginning of each day and re-run any 
time the nitrogen tank was changed, or when the type of sample being analyzed was 
changed. The data was baseline adjusted for the blank run within the instrument 
software.  
CD spectroscopy was completed on a Jasco J-815 spectrometer (Tokyo, Japan), 
and Jasco Spectra Manager version 1.54.03 (Build 1) software for CD analysis. All CD 
experiments were conducted under nitrogen flow.  For completing a secondary structure 
scan, the wavelength range was set from 300 nm to 190 nm with a data pitch of 1 nm in 
continuous scan mode, a constant temperature of 25 °C, a scan speed of 100 nm/min, 
response time of 2 secs, bandwidth of 1 nm.  An accumulation of 3 spectra were 
averaged before reporting.  Parameters for the melt studies were as follows: 25 to 90 
°C, data pitch of 0.2 °C, delay time was 10 sec, the temperature slope was 1 °C/min, 
sensitivity was standard (100 mdeg), response was 0.5 sec, bandwidth was set to 1 nm. 
The CD signal was measured at 222 nm. 
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Data collected was exported to .txt files, so plots could be re-constructed in 
Microsoft Excel.  Secondary structural elements, or percentages of α-helices and β-
sheets, were calculated on the Dichroweb website 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) using the K2D analysis program. 
The melt temperature (Tm) was calculated by importing the data from the melt plot into 
Microcal Origin 6.0 software and fitting the data to a sigmoidal curve. The inflection 
point in the sigmoidal curve (also calculated within the Microcal Origin software) was 
determined to be the melt temperature (Tm). 
5.2.4 Protease digestion   
To ensure that the deglycosylating enzyme, PNGase F, completely removed the 
glycans from the glycoprotein samples, deglycosylated RNase B and hLOXL2 (as well 
as glycosylated RNase B and hLOXL2 control samples) were prepared for protease 
digestion, followed by LC-MS and MS/MS analysis.  Urea was added to each of the 
samples, to a final concentration of 6 M, for protein denaturation.  To reduce the 
disulfide bonds in the proteins, TCEP was added to a final concentration of 5 mM, and 
the samples were allowed to incubate at room temperature for 1 hr.  Cysteine residues 
were then derivatized by the addition of IAA to 10 mM with incubation at room 
temperature in the dark for 1 hr, followed by the addition DTT to 10 mM to quench the 
alkylation reaction.  Samples were then diluted with buffer to a final urea concentration 
of 1 M.  Trypsin was added in a 1:30 enzyme:protein ratio, and samples were allowed to 
incubate for 18 hours at 37 °C.  The protease digestion was stopped by the addition of 1 
µL acetic acid for every 100 µL in solution.  Digested samples were concentrated in a 
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Labconco centrivap cold trap (Kansas City, MO) until the final protein concentration was 
~3 mg/mL, followed by storage at -20 °C until ready for LC-MS analysis. 
5.2.5 Liquid Chromatography/Mass Spectrometry 
For LC-MS and LC-MS/MS analysis of glycoproteins, 5 µL (~15 µg) of the 
proteolytically digested samples were injected onto a CVC MicroTech (Fontana, CA) 
C18 column (300 µm i.d., 5 cm length, and 3 µm particle size) that was attached to a 
Dionex UltiMate capillary HPLC system (Sunnyvale, CA) equipped with a FAMOS well 
plate autosampler and directly connected to an electrospray ionization linear ion trap 
Fourier transform ion cyclotron resonance mass spectrometer (ESI-LTQ-FTICRMS).  
Mobile phase HPLC solvents consisted of 99.9 % water + 0.1 % formic acid for solvent 
A and 99.9 % acetonitrile + 0.1 % formic acid for solvent B.  For separation of peptides 
and glycopeptides, solvent B was initially held at 5 % for 5 min, linearly increased to 40 
% over 50 min, increased further to 90 % in 10 min, held at 90 % B for 10 min, and re-
equilibrated before the next injection.  Between each glycoprotein sample injection, a 
short wash cycle and blank run were performed to ensure that no 
peptides/glycopeptides from previous runs were detected.  For mass spectrometry, the 
ESI source voltage was set to 2.8 kV; the capillary temperature was 200 °C; the 
capillary had an offset voltage of 47 V; the FT-ICR resolution was set to 25,000 for m/z 
400; and tandem mass spectrometry data were acquired in data-dependent mode.  The 
five most intense ions from an FT-ICR scan were chosen for CID (collision induced 
dissociation) analysis with a three min dynamic exclusion window and collision energy 
of 30%.   
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The glycosylated hLOXL2 sample was re-run on the same HPLC column 
connected to a Waters Acquity ultra performance liquid chromatography (UPLC) system 
(Milford, MA) using an electrospray linear ion trap mass spectrometer (ESI-LTQ Velos 
MS), ThermoScientific (San Jose, CA) for detection, because no glycopeptides were 
detected at one of the two glycosylation sites for hLOXL2 on the ESI-LTQ-FTICRMS).  
The LTQ Velos is known to have distinct advantages, such as higher sensitivity and 
shorter duty cycle, compared to the LTQ.21  To elute peptides and glycopeptides the 
solvent conditions began at 5% B and were linearly increased 10 % in 5 min, increased 
to 40 % B over 45 min, further increased to 90 % B in 10 min, held at 90 % B for 10 min, 
and re-equilibrated before the next injection.  The LTQ Velos MS parameters are as 
follows: 3 kV for ESI source voltage, 250 °C for capillary temperature, and data 
dependent mode was used for collection of MS/MS data by selecting the five most 
intense ions for collision induced dissociation (CID).  A 30% collision energy was used, 
along with a 3 min dynamic exclusion window. 
 MS and MS/MS data were manually assigned.  MS data was collected for RNase 
B and hLOXL2 before and after glycan removal with PNGase F to confirm that PNGase 
F completely removed the glycans from the glycoproteins. Therefore, only the peptides 
from the potential glycosylation sites were searched in the MS and MS/MS data.  For 
MS/MS analysis peptide and glycopeptides, the deglycosylated peptides needed to 
contain characteristic b and y ions, and glycosylated peptides needed to show losses of 
glycan residues.  For high resolution MS data collected on the FTICRMS, the 
monoisotopic m/z had to be within 20 ppm mass error to be considered a detected 
peptide or glycopeptide.  This high resolution mass spectrometric detection parameter 
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was relaxed for the hLOXL2 glycosylated sample that was run on the LTQ Velos MS 
because the instrument is a low resolution mass spectrometer.  Therefore, to be 
considered a detected peptide or glycopeptide in the LTQ Velos data, the peak had to 
be within 1 Da of the calculated m/z. 
5.3 Results and discussion 
CD spectroscopy was used to assess changes in structure and/or stability among 
glycoproteins containing high mannose type N-linked glycans after glycan removal.  
Two proteins were chosen for analysis.  The first was a model glycoprotein, 
ribonuclease B (RNase B), a fairly small glycoprotein (~15 kDa) with one N-linked 
glycosylation site containing high mannose type glycans.  After RNase B was analyzed, 
the method was applied to a protein that has potential as a glycoprotein pharmaceutical, 
human lysyl oxidase-like 2 (hLOXL2) glycoprotein. hLOXL2 is ~40 kDa and contains two 
N-linked glycosylation sites.  Chapter 3 describes the glycosylation present on hLOXL2 
and confirmed that the glycans are N-linked and of the high mannose type.   
Figure 1 illustrates a workflow of the experiments that were performed.  Part of 
the native (glycosylated) proteins were deglycosylated by the enzyme PNGase F, which 
cleaves the N-linked glycosylation between the Asn residue and the first N-
acetylglucosamine (HexNAc) glycan.  In the process of removing the glycan, the Asn 
residue is converted to an Asp residue (as shown in Figure 1, steps 1 and 2).  Before 
CD spectroscopy could be utilized for structural and stability analysis of the 
glycoproteins, the completeness of the glycan removal reaction was assessed by mass 
spectrometry.  A glycosylated and a deglycosylated sample were subjected to protease 
digestion (step 3 in Figure 1).  During this step, the proteins were cleaved into peptides 
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and glycopeptides.  After digestion, LC-MS and data dependent MS/MS was performed 
on the proteins (step 4 in Figure 1).  Once the deglycosylation conditions were validated 
to be effective at completely removing the glycan, the CD experiments were performed 
(step 5 in Figure 1).  Two different types of CD experiments were utilized to determine 
changes in glycoprotein structure and stability; a wavelength scan, for structural 
analysis, and a melt study, for stability. 
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Figure 1. Work flow for the studies in this chapter.  RNase B and hLOXL2 either remained in the native 
(glycosylated) form (step 1) or underwent glycan removal by PNGase F (step 2). Both glycosylated and 
deglycosylated forms of the proteins were also prepared for protease digestion (step 3), followed by 
HPLC-MS and MS/MS analysis (step 4) for validation of glycan removal. Both glycosylated and 
deglycosylated forms of the proteins were subjected to CD spectroscopy (step 5) where a secondary 




5.3.1 Validation of glycan removal 
In order to ensure that PNGase F effectively removed the glycans from the 
proteins, deglycosylated samples were proteolytically digested and then subjected to 
LC-MS and MS/MS analysis.  Because hLOXL2 contained two N-linked glycosylation 
sites, protease digestion before mass spectrometric analysis, as opposed to MS on the 
intact protein, would give the most complete compositional information.  Figure 2 
illustrates mass spectrometry data for the glycosylated and deglycosylated RNase B 
sample.  Figure 2A shows the high resolution mass spectrum, where all the glycoforms 
from RNase B were present with no peak corresponding to a non-glycosylated peptide.  
Figure 2B is the high resolution mass spectrum after deglycosylation.  As can be 
elucidated from Figure 2B, the glycans are not present in this spectrum, thereby 
illustrating that the deglycosylation reaction with PNGase F went to completion.  Figure 
2C and 2D are representative RNase B MS/MS data that were used to confirm the 
identities of the peaks present in Figure 2A and 2B.  Figure 2C is tandem mass 
spectrum from one of the glycopeptides present in RNase B.  The losses of glycan 
residues in Figure 2C are readily seen; they confirm the composition predicted from the 
high resolution mass spectrum in Figure 2A.  Figure 2D displays the MS/MS data for the 
deglycosylated peptide from RNase B, where the peptide was easily deduced by the 
presence of b and y ions for all but one peptide backbone cleavage at b1, which was 
beyond the lower limit of the scan range.  This spectrum, along with the mass spectrum 
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shown in Figure 2B, confirmed that the deglycosylated peptide was formed, and 
PNGase F successfully removed the glycans from RNase B.   
 
Figure 2.  Proteolytically digested RNase B mass spectra for glycosylated (A) and (C), as well as 
deglycosylated (B) and (D) forms.  (A)  Mass spectrum for glycosylated RNase B.  Glycopeptides were 
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detected, but not a nonglycosylated peptide.  (B) Mass spectrum for deglycosylated RNase B.   The 
glycosylated peptide was detected, but no glycopeptides.  (C) MS/MS data for a representative RNase  B 
glycopeptide for validation of the presence of glycans at the glycosylation site.  (D) MS/MS data for the 
deglycosylated RNase B peptide. 
 
After successful deglycosylation of RNase B in the native state with PNGase F, 
this approach was applied to hLOXL2 using the same digestion procedure.  The MS 
data was collected on both an ESI-LTQ-FTICRMS and an ESI-LTQ Velos MS with the 
same HPLC column for the glycosylated and deglycosylated forms of hLOXL2.  
Glycosylation was detected at both glycosylation sites with the ESI-LTQ Velos MS and 
no glycopeptides were detected in the deglycosylated samples (data not shown).  
hLOXL2 samples collected on the ESI-LTQ-FTICRMS contained glycopeptides at only 
one of the two N-linked glycosylation sites for the glycosylated samples.  No 
glycopeptides were detected in the deglycosylated hLOXL2 sample, similar to the ESI-
LTQ Velos MS data.  Figures 3 and 4 are representative MS and MS/MS spectra for 
glycosylated and de-glycosylated peptides at both N-linked glycosylation sites in 
hLOXL2.  Figure 3A and 3C show ESI-LTQ Velos MS data at the 
NGSLVWGMVCGQNWGIVEAMVVCR glycosylation site (because this glycosylation 
site was not detected in the ESI-LTQ-FTICRMS data).  Figure 3B and 3D show the 
same glycosylation site after deglycosylation where the spectra are from the ESI-LTQ-
FTICRMS data because the FT-MS data in Figure 3B has much higher resolution 
compared to the ESI-LTQ Velos MS and therefore a more confident assignment of the 
deglycosylated peptide is obtained.  Figure 3C and 3D both show representative 
MS/MS spectra for the glycosylated and deglycosylated forms of hLOXL2, respectively. 
The mass spectral data for the HYHSMEVFTHYDLLNLNGTK glycosylation site 
showed sufficient glycopeptide and deglycosylated peptide data with the ESI-LTQ-
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FTICRMS run.  Therefore, Figure 4 illustrates spectra from only the ESI-LTQ-FTICRMS 
because of the high mass accuracy obtained.  Like the other glycosylation site from 
hLOXL2, the MS data shown in Figure 4A and 4B illustrate that only glycopeptides were 
detected in the glycosylated sample (Figure 4A) and only the deglycosylated peptide 
was detected in the deglycosylated sample (Figure 4B).  Figure 4C and 4D show 
representative MS/MS data for the glycosylated and deglycosylated forms of this 
glycosylation site, respectively.  The hLOXL2 mass spectrometry data, like RNase B, 
illustrated that no glycopeptides were detected in the deglycosylated samples, once 
again confirming that PNGase F successfully cleaved the glycans at both glycosylation 





Figure 3.  hLOXL2 mass spectra of glycopeptides (A) and (C), as well as the deglycosylated peptide (B) 
and (C) at 1 of the 2 N-linked glycosylation sites.  (A) MS1 spectrum for glycopeptides present, with no 
non-glycosylated peptide detected.  (B) MS1 spectrum for the deglycosylated sample illustrating no 
glycopeptides detected.  Even though a peak is present at m/z 1200.203 in (B), the MS/MS data confirms 
that it is not a glycopeptide (data not shown).  (C) Glycopeptide MS/MS spectrum for validation of the 
presence of glycans at the glycosylation site, showing typical glycan losses expected.  (D) Peptide 
spectrum of the N-linked glycosylation site after deglycosylation with PNGase F.  
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Figure 4.  hLOXL2 mass spectra at the other N-linked glycosylation site illustrating glycosylated (A) and 
(C), as well as deglycosylated (B) and (D) sample.  (A) MS1 spectrum for the glycosylated hLOXL2 
sample where glycopeptides (but not a non-glycosylated peptide) were detected.  (B) MS1 spectrum of 
deglycosylated hLOXL2 where no glycopeptide peaks were detected.  (C) Glycopeptide MS/MS spectrum 
for validation of the presence of glycans at the glycosylation site.  (D) Peptide spectrum of the N-linked 
glycosylation site after deglycosylation with PNGase F. 
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5.3.2 Circular dichroism analysis on glycosylated and deglycosylated proteins  
Circular dichroism was performed on both RNase B and hLOXL2 to assess if 
changes could be detected in the secondary structure and in the stability of the proteins 
before and after deglycosylation with PNGase F.  To ensure that PNGase F was not 
interfering in the CD analysis, since PNGase F is also a protein, the deglycosylating 
enzyme was added to the blank for the deglycosylated protein samples, whereas only 
buffer was added to the blank for the glycosylated samples.  Two different types of CD 
analysis were performed on each of the proteins.  The first type of CD analysis was a 
secondary structural scan where the wavelengths in the far UV region (260 nm – 190 
nm) were analyzed at a constant temperature for changes in ellipticity indicative of the 
secondary structural elements of the proteins.  The second CD scan type was a stability 
experiment, or melt study, where the change in ellipticity was assessed as the 
temperature was increased and the wavelength was kept constant at 222 nm (a minima 
observed for alpha helical content).  A typical melt study results in a sigmoidal curve, 
where the inflection point, or melt temperature (Tm), is where half the protein is folded 
and half is unfolded.  The higher the Tm, the more stable the protein. 
5.3.2.1 CD Secondary Structure Results 
Figure 5A illustrates the CD secondary structural scans for glycosylated and 
deglycosylated RNase B samples.  Four experiments were averaged together for each 
sample and plotted. As is clearly seen in the Figure, there is very little difference 
between the glycosylated and deglycosylated spectra. It is expected that RNase B 
would have a similar CD spectrum without glycosylated present, as RNase A is native 
nonglycosylated RNase B, with the same protein sequence and structure. Table 1 
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describes the secondary structural results from the glycosylated and deglycosylated 
forms of RNase B, where the secondary structure was calculated to be the same.  The 
literature contains estimates for alpha helical content from RNase B X-ray 
crystallography data between 6 and 18 %, and the percentage of random coil between 
46 and 58 %.22, 23  The results obtained here fall within the ranges from the literature.  
Additionally, no changes in structure were detected by CD by deglycosylating RNase B. 
 
Table 1. RNase B secondary structural elements as calculated in the Dichroweb K2D analysis program. 
 
 α-helix β-sheet Random coil 
Glycosylated 0.16 0.33 0.51 






Figure 5. (A) Secondary structure plot of the glycosylated and deglycosylated forms of RNase B.  (B) 
Secondary structure plot of the glycosylated and deglycosylated forms of hLOXL2.   
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Figure 5B illustrates the CD secondary structural scans performed on hLOXL2 
before and after deglycosylation with PNGase F after averaging 3 different CD runs.  
Like RNase B, the hLOXL2 results show very similar scans to one another indicating 
that removal of glycans most likely did not alter the protein structure.  Table 2 describes 
the secondary structure results for hLOXL2 broken down by alpha helical, beta sheet, 
and random coil content.  Because this is a novel recombinant protein, as well as a 
truncated version compared to endogenous hLOXL2, there is no other data for 
comparison of these results. Therefore, these data are the first to demonstrate that this 
protein’s structure is unaltered when it undergoes deglycosylation under non-denaturing 
conditions.   
 
 
Table 2. hLOXL2 secondary structural elements as calculated using Dichroweb’s K2D analysis program. 
 
 α-helix β-sheet Random coil 
Glycosylated 0.19 0.32 0.49 




5.3.2.2 Melt studies using circular dichroism spectroscopy 
In addition to analyzing the secondary structure of RNase B and hLOXL2 by 
circular dichroism, a second type of CD experiment was performed to assess changes 
in protein stability due to glycosylation.  It has been shown previously in the literature 
that there is a slight decrease in protein stability in RNase A (the naturally occurring 
deglycosylated form) compared to RNase B.24-27  However, other research has 
indicated that the decrease in stability upon deglycosylation is either negligible27 or due 
to steric hindrance of the glycan,29 as most of the literature studies measure RNase B 
stability by how well it is cleaved by different proteases.29, 30  In this work, a melt study 
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using CD spectroscopy was performed to assess changes in protein thermal stability in 
the glycosylated and deglycosylated forms.  Figure 6A illustrates the results from the 
melt study on RNase B.  The ellipticity was measured at 222 nm, which is one minimum 
observed in CD secondary structure plots corresponding to alpha helical content.16, 31  
As a protein is heated and unfolded, its alpha helical content decreases;  thus, the 
ellipticity becomes less negative.16, 31  Figure 6A also shows the characteristic sigmoidal 
curve that is observed in CD melt studies. The calculated Tm from the inflection point in 
the plot from Figure 6A for the glycosylated and deglycosylated RNase B was 65.6 °C 
and 65.8 °C, respectively.  These results show that there is effectively no change in Tm 
due to removal of glycans using circular dichroism to determine protein stability. 
After obtaining the results from RNase B that illustrate no difference between the 
glycosylated and deglycosylated forms’ thermal stability, hLOXL2 was also subjected to 
a melt study using CD spectroscopy. The results from the melt study of hLOXL2 were 
inconclusive.  Rather than slowly unfolding as the temperature was increased, hLOXL2  
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Figure 6.  (A) Melt study plot of the glycosylated and deglycosylated forms of RNase B. (B) Melt study 
plot of the deglycosylated form of hLOXL2 illustrating protein aggregation as the temperature was 
increased. Similar results were detected in the glycosylated hLOLX2 melt plots.   
 
 161 
(both the glycosylated and deglycosylated forms) stayed at the same relative ellipticity 
until about 55 °C.  At higher temperatures, the ellipticity increased gradually indicating 
that the protein was becoming more structured. Unfortunately, rather than unfolding, like 
RNase B, hLOXL2 was aggregating and precipitating out of solution, as solid precipitate 
was observed in the cuvette immediately after the melt studies were completed.  Figure 
6B is an example from one melt study that was completed for hLOXL2 in the 
deglycosylated form.  All hLOXL2 melt experiments resulted in similar plots.  Therefore, 
a Tm could not be calculated for hLOXL2.  Since the secondary structure of hLOXL2 
was very similar in both the glycosylated and deglycosylated forms, and since both 
proteins behaved identically during the melt studies, it is probable that removing the 
glycans had minimal or no effect on the stability of the protein. 
5.4 Concluding remarks 
 CD spectroscopy was used to analyze glycoproteins containing high mannose 
type N-linked glycosylation to determine if changes in structure or protein stability were 
detected upon deglycosylation of the proteins with the enzyme PNGase F.  RNase B 
and hLOXL2 were successfully deglycosylated, as mass spectrometry experiments 
confirmed. For analysis of secondary structure by CD spectroscopy, both proteins 
exhibited no change in the secondary structural elements upon glycan removal.  
Stability analysis by CD spectroscopy was successful for RNase B.  After removing the 
glycans, no effective change was detected in the Tm for RNase B, indicating that the 
protein stability was not changed.  Stability analysis on hLOXL2 was inconclusive 
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